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vSummary
Cardiovascular diseases remain the leading causes of death worldwide, accounting
for 17.7 million deaths every year — 31% of all global deaths. Atherosclerosis is
an underlying disease process in blood vessels that leads to the accumulation of
cholesterol plaques and a narrowing of the arterial lumen. If the plaque bursts, the
components are flushed into the bloodstream, triggering intravascular thrombosis
and leading to vascular occlusions. Heart attack or stroke are the most dangerous
medical consequences of this. In such an event, time is of utmost importance because
the infarcted organ suffers from necrosis without re-establishment of blood perfusion
within a few minutes. Currently, emergency treatment provided in the ambulance
involves intravenous injection of vasodilators that act systemically to dilate blood
vessels and re-establish blood supply. However, this works systemically and even
at a low dose lead to peripheral resistance decrease of the vessels and thereby hy-
potension. This generally inhibits the blood perfusion and thus the drug cannot
work optimally at the location of the constricted vessel. Therefore, the develop-
ment of a smart and effective drug delivery system, capable of releasing the drug
locally, is desired. Critically constricted arteries give rise to increased wall shear
stress that can be used as a physical trigger to release the therapeutics. Liposomes
belong to the most attractive carriers for drug targeting in medical fields. Recently,
mechano-responsive liposomes prepared from artificial phospholipids were suggested
as nanocontainers for delivery and release of vasodilators at constrictions of arteries.
This thesis project gives insight into the physicochemical properties of the mechano-
responsive liposomes, determines their thermal stability at physiologically relevant
body temperatures, and demonstrates their in vitro immunocompatibility.
The preliminary characterization of nanometer-size liposomes is essential for the
development of clinically relevant drug delivery systems. The mechano-sensitive
liposomes Pad-PC-Pad and Rad-PC-Rad were studied by means of dynamic light
scattering and transmission electron microscopy at cryogenic temperatures to de-
termine size distribution and shape. In both cases, the liposomes were found to be
around 100 nm in size with a variety of shapes. To prevent liposome aggregation
as a consequence of the low zeta potential, a steric stabilization using polyethylene-
glycol-grafted phospholipids was applied.
To ensure mechano-responsive behavior at body temperature, the liposomes’ struc-
ture should be stable at physiological and elevated body temperatures. Therefore,
the structural changes of liposomes were evaluated in a temperature range from 22 to
42 °C. Small-angle neutron scattering was used to measure the radius, eccentricity,
and bilayer thickness of liposomes. Pad-PC-Pad liposomes already undergo struc-
tural changes at 35 °C. Further heating to 42 °C and subsequent cooling to room
temperature resulted in a decreased eccentricity by an order of magnitude and a 20%
increase of bilayer thickness, indicating the loss of membrane interdigitation. Rad-
PC-Rad liposomes, however, show thermal stability up to 42 °C. Thus, Rad-PC-Rad
liposomes possess sufficient thermal stability for drug delivery to atherosclerotic hu-
vi
man blood vessels.
To advance this technology towards clinical applications, the in vitro immunocom-
patibility of liposomes was investigated. The systemic administration of liposomes
may trigger an immediate activation of the immune system, resulting in a hyper-
sensitivity reaction. This reaction is driven by the activation of the complement
system, which can stimulate the production of pro-inflammatory cytokines. Ex-
periments demonstrated that both the Pad-PC-Pad and Rad-PC-Rad liposomal
formulations exhibited low-to-moderate levels of complement proteins compared to
the Food-and-Drug-Administration-approved liposomal drugs such as Doxil® and
AmBisome®. Within the restricted number of individuals, one outliner was detected,
suggesting that a substantially higher number of donors should be incorporated into
future studies.
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Zusammenfassung
Herz-Kreislauf-Erkrankungen sind weltweit die häufigste Todesursache. 17,7 Millio-
nen Menschen sterben jährlich. Das sind 31% aller Todesfälle. Atherosklerose führt
in Blutgefässen zu Plaque und einer Verengung des Querschnitts. Platzt eine Plaque,
so werden die Bestandteile in die Blutbahn geschwemmt, lösen eine intravaskuläre
Thrombose aus und führen zu Gefäßverschlüssen. Herzinfarkt oder Schlaganfall sind
die gefährlichsten medizinischen Konsequenzen davon. In derartigen Fällen spielt die
Zeit eine zentrale Rolle. Da in wenigen Minuten der infarzierte Organteil ohne rasche
Retablierung der Blutperfusion, langsam nekrotisiert. Bereits im Krankenwagen wird
dem Patienten ein gefässerweiterndes Medikament gespritzt, um das lokale Gefäss
zu erweitern und die Blutversorgung zu retablieren. Nur wirkt das systemisch und
führt bei schon geringer Dosis zur peripheren Resistenzabnahme der Gefässe und
dabei zu einer Hypotonie. Diese Hypotonie hemmt allgemein die organische Blut-
perfusion und somit kann das Medikament lokal nicht optimal wirken. Deshalb ist
die Entwicklung von einer pfiffigen und wirksamen Medikamentenfreisetzung an den
Verengungen der Gefässe äusserst wünschenswert. Bedenklich verengte Blutgefässe
führen zu einer erhöhten Scherspannung, die man als Steuerimpuls für die Wirkstoff-
freisetzung nutzen kann. Liposomen gehören zu den attraktivsten Trägersystemen in
der Medizin. Unlängst wurde vorgeschlagen, dass man mechanisch reaktive Liposo-
me auf Basis von künstlichen Phospholipiden als Nano-Container für die Zuführung
und Freisetzung von gefässerweiternden Medikamenten an die krankhaften Gefäss-
verengungen nutzen kann.
Das Dissertationsprojekt führt zu Erkenntnissen über die physikalisch-chemischen
Eigenschaften der mechanisch reaktiven Liposome, ihre thermische Stabilität bei
physiologisch relevanten Körpertemperaturen und zeigt ihre Immunverträglichkeit.
Die mechanisch reaktiven Liposome Pad-PC-Pad und Rad-PC-Rad wurden mittels
dynamischer Lichtstreuung und Tieftemperatur-Transmissionselektronenmikroskopie
untersucht, um deren Grösse und Form zu bestimmen. In beiden Fällen hatten die
vielfältig geformten Liposome eine Grösse von etwa 100 nm. Um die Zusammenla-
gerung der Liposome als Folge des geringen Zeta-Potentials zu verhindern, wurde
als räumlicher Stabilisator Polyglykol auf die Phospholipide aufgepfropft.
Um die mechanische Reaktionsfähigkeit bei Körpertemperatur zu garantieren, soll-
ten die Struktur der Liposome auch bei erhöhter Körpertemperatur stabil sein. Des-
halb wurden die strukturellen änderungen im Temperaturbereich zwischen 22 und
42 °C ausgewertet. Kleinwinkel-Neutronen-Streuung wurde verwendet, um den Radi-
us und die Exzentrizität der Liposome sowie die Dicke der zugehörigen Phospholipid-
Doppelschicht zu vermessen. Pad-PC-Pad Liposome zeigen bereits bei 35 °C struk-
turelle Veränderungen. Das weitere Heizen auf 42 °C und anschliessende Abkühlen
auf Raumtemperatur führt zu einer um eine Grössenordnung verringerten Exzentri-
zität und einem 20%igen Anstieg der Doppellagendicke. Diese Beobachtung deutet
auf den Verlust der wechselseitigen Verzahnung der Lipide hin. Demgegenüber sind
Rad-PC-Rad Liposome bis 42 °C thermisch stabil. Folglich sind Rad-PC-Rad Lipo-
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some für die Wirkstofffreisetzung in atherosklerotischen Blutgefässen des Menschen
thermisch genügend stabil.
Um diese Technologie in Richtung klinischer Anwendungen voranzutreiben, wurde
die Immunverträglichkeit der Liposome in vitro untersucht. Die systemische Gabe
der Liposome könnte eine sofortige Aktivierung des Immunsystems auslösen und
zu überempfindlichkeitsreaktionen führen. Eine derartige Reaktion wird durch die
Aktivierung des Komplementsystems getrieben, die die Produktion von proinflam-
matorischen Cytokinen anregen kann. Die Experimente haben gezeigt, dass sowohl
Pad-PC-Pad als auch Rad-PC-Rad Liposome im Vergleich zu von der FDA aner-
kannten Liposomen-basierten Medikamenten wie Doxil® and AmBisome® nur einen
geringen Gehalt an Komplementärproteinen aufweisen. Innerhalb der eingeschränk-
ten Anzahl an Spendern wurde ein Ausreisser gefunden. Deshalb sollte die Zahl der
Spender für zukünftige Studien substantiell erhöht werden.
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11 Introduction
According to the World Health Organization, cardiovascular diseases (CVDs) remain
the major cause of morbidity and mortality worldwide, resulting in 17.7 million
deaths per year [1]. 80% of all CVD-related deaths are due to heart attacks and
strokes, with atherosclerosis the main contributor. Atherosclerosis is a complex
inflammatory disease related to the damage and inflammation of endothelium as
well as the accumulation of lipids and white blood cells, the proliferation of intimal-
smooth-muscle cells, and finally tissue calcification that leads to a fibro-fatty plaque
formation. Major risk factors for atherosclerosis include high cholesterol levels and
high blood pressure. Fatty deposits (plaques) accumulate over years along the inside
of artery walls, narrowing the lumen of the artery and obstructing the blood flow.
Further growth of atherosclerotic plaque or its rupture triggers the formation of a
blood clot, preventing oxygen supply to the heart and brain.
After a myocardial infarction or stroke, time is the most important factor in the
treatment procedure. Treatments are mainly based on restoring the oxygenation
and improving arterial hemodynamics. The established therapeutic option for the
first line treatment of heart attack in ambulances involves systemic administration of
vasodilators such as nitroglycerin (NTG) [2,3]. However, their use is limited by the
risk of hypotension and subsequent end-organ hypoperfusion. Inappropriate vasodi-
latation may induce a steep reduction in blood pressure, resulting in hemodynamic
instability, ischemia, or renal failure, all of which leads to increased mortality [4].
Thrombolytic agents, such as tissue plasminogen activator (tPA) have been devel-
oped for dissolving blood clots with the aim of restoring and improving the blood
flow [5]. However, indications of using free tPA are limited as its systemic adminis-
tration carries a risk of hemorrhage that may be fatal [6].
The risk of systemic side effects from vasodilators or thrombolytic agents can be
reduced through the development of a controlled, local drug delivery platform for the
cardiovascular system. To this end, there has been a great focus on engineered bio-
nanomaterials such as liposomes, polymeric, magnetic, and gold nanoparticles [7–
9]. Liposomes are composed of phospholipids that self-assembly into closed bilayer
structures in aqueous systems due to their amphiphilic nature. Nowadays, liposomes
are the most common and well-investigated nanocarriers for drug delivery [10]. Their
ability to encapsulate both hydrophilic and hydrophobic drugs in combination with
their biocompatibility, biodegradability, and the possibility of controllable release
kinetics, make liposomes an attractive pharmaceutical carrier. The release of the
liposomes’ cargo can be achieved upon various physical or biochemical stimuli, i.e.
changes in shear stress, temperature, ultrasound, light, pH, enzymatic or redox
reactions [11]. This thesis focuses on mechano-responsive liposomes that can be
triggered by shear stress.
The mean physiologic wall shear stress in the human arterial system varies between
0.1 − 1.2 Pa [12]. Critically constricted arteries are characterized by substantially
increased wall shear stress, at least one order of magnitude higher than the healthy
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case (14.2 Pa at 80% of stenosis [13]). This increased shear stress can be used as
a physical trigger to disrupt the liposome membrane, enabling drug release. The
concept of shear stress responsive drug delivery has been previously proposed by two
research groups. One approach is based on the delivery of microscale aggregates of
nanoparticles coated with tPA to the obstructed blood vessels [14]. When exposed
to abnormally high fluid shear stress, these aggregates break up into nanoscale
components and induce rapid clot dissolution and restore normal flow [14]. Another
approach was proposed by members of our research project based on delivery of
mechano-responsive liposomes loaded with a vasodilator to the constricted arteries
[15,16].
In order to tailor the chemical composition and subsequent physical properties of
mechano-responsive liposomes, the shear stress parameters of healthy and stenosed
arteries need to be determined. Arterial wall shear stress can be computed using
flow simulations, which in turn require information about the radius of the arterial
lumen. Arterial morphology is often studied by means of histology, which can only
offer two-dimensional information, significantly limiting its application to blood flow
simulations. Additionally, tissue morphology can be altered due to preparation arte-
facts, which can originate from decalcification, cutting, and embedding, leading to
tissue shrinkage or deformation. X-ray tomography can overcome this challenge, pro-
viding a non-destructive, quantitative 3D visualization of plaque-containing blood
vessels at micrometer level [17–19]. Moreover, X-ray tomography allows for lumen
segmentation — a crucial step for subsequent flow simulation analysis.
As part of this thesis, tomography datasets of a diseased human coronary artery were
acquired using advanced laboratory X-ray micro computed tomography (µCT) sys-
tem in absorption contrast mode, which is well suited for discriminating anatomical
structures with significant differences in X-ray absorption, including the determina-
tion of plaque morphology within artery and determination of the extent of stenosis
resulting in lumen segmentation [20].
The human artery containing calcified atherosclerotic plaque was embedded in a
paraffin and measured before and after decalcification to determine the cross-section
of the lumen, the non-constricted area of the artery, and the changes in cross-section
due to decalcification procedure.
Figure 1.1 compares virtual slices through the tomography dataset of the plaque-
containing artery (A: top view, C: lateral view) and the same artery after decalcifi-
cation process (B: top view, D: lateral view). In Figure 1.1A, the artery walls and
plaque are clearly visible; however, the contrast in the surrounding fatty tissue is
low. On the other hand, in Figure 1.1B, the artery wall is clearly visible thanks to
better contrast. However, hard tissue residuals from the plaque decalcification are
still present in the surrounding tissue (shown by yellow arrows). The presence of
preparation artefacts including air bubble in the left lumen of calcified artery (Figure
1.1A) and small paraffin cracks inside the lumens of the decalcified artery (Figure
1.1B) are visible in the tomography datasets. Streak artefacts (whitish color on red
background) around the highly X-ray absorbing calcified plaque were observed in
the calcified sample (Figure 1.1A). These artefacts overlap with the morphology of
the lumen and make segmentation more challenging.
The cross-sectional area of both the calcified and decalcified artery samples was
extracted using the region-growing segmentation tool of VG Studio Max 2.1, which
is a fast and convenient method to obtain the morphology of the lumen. The cross-
3Figure 1.1: Axial slices of a calcified (A: top view, C: lateral view) and decalcified (B: top view,
D: lateral view) human coronary artery embedded in paraffin, measured with absorption contrast
µCT. Region 1 (colored in green), region 2 (blue) and region 3 (red) in images A and B correspond
to the cross-sectional area of three lumens. Region 3 of image A shows the calcified plaque, depicted
in bright white — indicating high X-ray absorption.
sectional area was calculated and the results are presented in Table 1.1.
Numbers and related color indicate each region of the artery. The cross-sectional
area of the segmented slice between the two samples before and after decalcification
process decreased from 0.84 to 0.80 mm2 (Region 1), from 2.42 to 2.40 mm2 (Region
2), and from 1.86 to 1.82 mm2 (Region 3), although the decrease was around the size
of the measurement uncertainty. The artery shrinkage and the resulting decrease
in lumen area may be caused by the chemical treatment during the decalcification
process. Despite the removal of the atherosclerotic plaque in the Region 3, the area
did not notably decrease, because the soft tissue was still present. The area of the
calcified plaque was 1.07 mm2, whereas the area of the soft tissue residuals after
decalcification was 1.02 mm2. Comparing these two slices from calcified and de-
calcified datasets, the decalcification process does not significantly change the cross
section of the lumen. The datasets of unstained soft tissue showed surprisingly high
contrast. One can reasonably assume that dehydration is the key factor, as it leads
to increased tissue density, and thus, different attenuation values. A recent study
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Table 1.1: The cross-sectional area of the artery lumen.
Calcified artery area, mm2 Decalcified artery area, mm2
Region 1 (green) 0.84± 0.02 0.80± 0.02
Region 2 (blue) 2.42± 0.02 2.40± 0.02
Region 3 (red) 1.86± 0.02 1.82± 0.02
with high-resolution hard X-ray tomography demonstrated that paraffin embedding
gives rise to an anisotropic shrinkage up to 65% with respect to formalin fixed tis-
sues, suggesting that the artery lumen should be extracted before decalcification
and paraffin embedding [19].
The lumen area calculated in this study is a starting point for the complete segmen-
tation of the lumen, which is a prerequisite for quantitative blood flow simulations.
These results demonstrate that µCT is a valuable tool to study the morphology of
diseased atherosclerotic artery.
Liposomes have demonstrated significant therapeutic advantages, but their clini-
cal translation remains limited by the immunological barrier. Investigation of li-
posomes’ interactions with the patient’s immune system in vitro can help to pre-
vent serious and potentially lethal reactions during clinical evaluation. When intra-
venously administered, liposomes immediately interact with blood components such
as serum proteins, which function is to assist the innate immunity in rapid clearance
of pathogens and other foreign dangerous materials. It is therefore expected that
liposomes will be recognized by the immune system. The development of immuno-
genic reactions towards liposomes may lead to the prevention of targeted delivery, an
altered pharmacokinetics, a loss of therapeutic effect, and the rise of potentially seri-
ous toxicities [21,22]. Through 2017, ten liposomal formulations have been approved
by Food and Drug Administration (FDA) [23, 24]. However, lipid-based nanopar-
ticles are one of the most frequent nanomedicines to induce activation of immune
system [25]. A very recent study reported that out of 15 nanotechnology-based
drug products that are known to induce infusion reactions, 7 are liposomes [26]. An
example of an acute adverse immune reaction caused by liposomes is complement
activation-related pseudoallergy (CARPA) [22,27,28]. CARPA is non-IgE-mediated
hypersensitivity reaction that can cause symptoms involving many organ systems
(e.g. anaphylaxis, hypo- and hypertension, fever, headache, cardiopulmonary dis-
tress, etc.) with high reaction rate (up to 45%) [27]. The mechanisms and biolog-
ical consequences of liposomes triggering the activation of the complement system
are not completely understood. However, there is clear evidence that liposomes’
physicochemical properties, including size, size distribution, composition, surface
characteristics, and stability affect activation of immune system [25]. Therefore, the
modulation of these characteristics can prolong the in vivo circulation of liposomes
and their subsequent efficacy. Recently, a preclinical strategy for evaluation of po-
tential adverse effects induced by nanomedicines was proposed [29]. This strategy
is based on a three-tiered approach, combining physicochemical characterization of
engineered nanomedicines, nanoparticles interaction and a hazard assessment fea-
turing the detection of complement activation [29]. More importantly, in vitro and
in vivo assessments of complement reactions are recommended by the European
Medicines Agency as a preclinical assay in the development of liposomal drugs [30].
The level of complement activation can be verified by identifying the complement
5split products in human sera, using enzyme-linked immunosorbent assay (ELISA).
In Section 2.1, an in vitro study on the immunological response towards Pad-PC-
Pad liposomes is reported. Bare and NTG-loaded Pad-PC-Pad liposomes, with and
without PEG, at two concentrations were incubated with human sera. The con-
centration of complement proteins C4d, Bb and SC5b-9 was determined. Elevated
level of C4d or Bb protein is evidence for the involvement of classical and lectin
or alternative complement pathways, respectively. The level of complement acti-
vation induced by Pad-PC-Pad liposomes was compared to that one triggered by
FDA-approved drugs (e.g. Doxil®, Abelcet®).
In Section 2.2, an in vitro study on the immunocompatibility of Rad-PC-Rad li-
posomes was conducted. In this work the activation of the complement system
was expanded to the detection of C3a and C5a anaphylatoxins and release of pro-
inflammatory cytokines (e.g. IL-1β, IL-6, IL-8, IL-12, TNF-α). The dependency
between complement-induced anaphylatoxins production and secretion of cytokines
was demonstrated [31]. Uncontrolled release of cytokines can induce potentially
life-threatening conditions, including anaphylaxis and cytokine storm. Complement
activation and cytokine release was suggested within a tiered approach for in vitro
assessment of nanoparticle immunocompatibility [32]. Therefore, questions arose of
whether Rad-PC-Rad liposomes carry a risk of potential in vivo hypersensitivity and
if it can cause increased production of pro-inflammatory cytokines. Four Rad-PC-
Rad liposomal formulations, bare and NTG-loaded, with and without PEG, at two
phospholipid concentrations were incubated with human sera. For the detection of
complement proteins concentration, samples were analyzed using ELISA. The level
of complement activation induced by Rad-PC-Rad liposomes was compared to that
one triggered by FDA-approved liposomal drugs (e.g. Doxil®, AmBisome®). The
cytokine immunoassay was performed by incubation of Rad-PC-Rad liposomes with
isolated leukocytes and with human whole blood. Samples were analyzed using a
flow cytometry assay.
Liposome stability is a major requirement for drug delivery. The drug encapsu-
lated by the liposome should stay confined inside until the certain release stimuli
being applied. To ensure an appropriate mechanism for action, liposome structural
parameters have to be known and controlled. Shear-stress sensitive liposomes are in-
tended for intravenous injection to the human body, therefore, they have to maintain
structural stability over a physiologically relevant temperature range. The normal
human body temperature range is typically stated as 36.5− 37.5 °C. However, ther-
apeutic hypothermia (< 35 °C) is routinely induced during cardiac surgery, and is
recommended as a treatment strategy for cardiac arrest in international resuscita-
tion guidelines [33]. The results of clinical trials demonstrated that mild therapeutic
hypothermia (32− 34 °C) showed an improvement of patients’ survival [34, 35]. At
the other extreme, hyperthermia (37.5 − 38.5 °C) and hyperpyrexia (40 − 41 °C)
of the human body have prevalent occasion and were investigated in detail [36].
Even higher temperatures (41.6 − 42 °C), known as critical thermal maximum of
human body, might occur in life threatening conditions [37,38]. Therefore, in order
to cover the potentially relevant physiological temperature range, liposomes were
investigated over the 22− 42 °C. Then samples were cooled down back to 22 °C to
determine the reversibility of observed structural changes.
Pad-PC-Pad and Rad-PC-Rad liposomes, previously identified as potential candi-
dates for targeted drug delivery to the atherosclerotic arteries, were extensively
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studied [15, 39–43]. These liposomes along with a library of specifically modified
1,3-substituted lipids with 16:0-18:0 cis-double bonds and ester, amide and urea
linkers were synthesized and studied in order to understand the unique behavior
of mechanoresponsive liposomes [44]. Dynamic light scattering (DLS) was used
to measure overall size of the liposomes. Liposome shape was investigated using
transmission electron microscopy at cryogenic temperatures (cryo-TEM). However,
cryo-TEM is limited by the number of liposomes observed, therefore a technique
involving statistical averaging is desirable to provide a measurement of entire sam-
ple. Small-angle neutron scattering (SANS) was applied, allowing for higher reso-
lution and statistical averaging. Previous studies have employed SANS to provide
quantitative information about the liposomes’ organization at the nanoscale and to
investigate their structure-function relationship [45]. In our study, liposome size and
shape as determined by DLS and cryo-TEM were used as starting values for SANS
data fitting.
The results presented in the Section 2.3 provide quantitative information on the
change in liposomes structural parameters (e.g. bilayer thickness, radius, eccentric-
ity) across the whole range of physiologically relevant temperatures, as determined
from the analysis of SANS data.
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ABSTRACT 
For natural scientists and engineers, learning from nature has tradition and is often driven by bio-inspired processes and 
materials. For example, engineers have designed multifunctional materials with hierarchical structures. Lipid bilayers, 
the principal components of cell membranes, can form vesicles, termed liposomes. Such liposomes are usually 
recognized as foreign by the immune system of a patient, which makes it challenging to use liposomes as containers for 
targeted drug delivery. There are, however, promising non-spherical, mechano-sensitive, artificial liposomes about 
100 nm in diameter, which were recently identified. These bio-inspired containers offer a wide range of applications. In 
particular, the targeted release at critically stenosed arteries formed as a result of atherosclerosis significantly reduces the 
undesired side effects such as a drop of blood pressure. It is well known that FDA-approved liposomal drugs, currently 
on the market, often induce adverse immune responses. Therefore, to exclude the hypersensitivity of the recently 
discovered mechano-sensitive liposomes, we have performed in vitro complement activation experiments and related 
animal studies with pigs. Recently, it has been shown that the drug-free Pad-PC-Pad liposomes surprisingly lack any 
complement activation. In this study, we demonstrate that nitroglycerin-loaded liposomes with relevant human 
therapeutic dosage exhibit low complement activation compared to the FDA-approved phospholipid drugs, including 
Abelcet. Furthermore, the liposomal suspensions applied are stable for a period of more than two months. Consequently, 
the non-spherical liposomes of nanometer size we have developed are promising containers for physically triggered, 
targeted drug delivery. 
Keywords: Nanotechnology, targeted drug delivery, atherosclerosis, biomimetic, liposome, shear stress, 
hypersensitivity, complement activation.  
 
1. INTRODUCTION  
Nanomedicine is at the frontline of nowadays therapy for targeted drug delivery and the global nanomedicine market 
continues to grow. It is expected to reach $528 billion by 2019 [1]. The goal of such transporting system is to safely 
assist the delivery of a pharmaceutical compound to a specific targeted within the body, increasing the therapeutic index 
of the drug and decreasing acute side effects.  
Nature has inspired most of the successfully introduced technologies, that are used in biomedical applications. Bio-
mimetical systems were developed, based on the way how the natural systems are constructed. For instance, biological 
membranes, representing highly complex and dynamic structures, are mimicked in lipid self-assembly liposomes, closed, 
spherical vesicles, trapping an aqueous solution into inner environment (see Figure 1). 
The spontaneous liposome formation is initiated when phospholipids, with two hydrophobic chains and a hydrophilic 
polar head group, are exposed to an aqueous environment. This configuration is energetically favored. Liposomes were 
firstly described by Bangham and Horne in 1964 [2]. Inspired by this architecture, liposomes appeared as a suitable 
concept for the development of drug delivery systems [3-5].  
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2. MATERIALS AND METHODS 
2.1 Materials for in vitro ELISA assay 
Pad-PC-Pad (1,3-palmitoylamido-1,3-deoxy-sn-glycero-2-phosphatidylcholine) has been synthetized following the 
previously reported protocol [6, 7]. DSPE-PEG2000 (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[amino(polyethylene glycol)-2000]) was a generous gift from Lipoid GmbH (Germany). Commercial nitroglycerin 
(NTG) solution “Perlinganit” was purchased from UCB-Pharma AG (Switzerland), Zymosan - from Sigma-Aldrich Ltd. 
(Hungary) and saline solution (0.9 %, 308 mOsm/L) - from Teva Pharmaceuticals Zrt (Hungary). Doxil and Abelcet 
were used as purchased by the Nanomedicine Research and Education Center, Semmelweis University (Hungary). 
Human serum and pig plasma samples were obtained from healthy donors at the Semmelweis University, according to an 
approved phlebotomy protocol. Until usage, the samples were stored at a temperature of -80 °C. For the determination of 
classical, alternative pathways and terminal complement complex the following ELISA kits were used: MicroVue C4d, 
Bb and SC5b-9 Plus. ELISA kits were purchased from Quidel Corp. (San Diego, CA, USA). 
2.2 Preparation of shear stress sensitive Pad-PC-Pad liposomes 
Three liposomal formulations were prepared, namely A (Pad-PC-Pad/DSPE-PEG2000), B (Pad-PC-Pad/DSPE-PEG2000) 
and C (Pad-PC-Pad). Liposomes were prepared from Pad-PC-Pad and DSPE-PEG2000 phospholipids in compliance with 
a previously reported protocol [7], using the thin film method [15, 16]. Briefly, the lyophilized phospholipids were 
dissolved in chloroform, in appropriate molar ratios: A – 95:5, B – 95:5, C – 100 mol%. The initial phospholipid 
concentration was 10 mg/mL. Then, the solvent was removed by rotatory evaporation under reduced pressure, followed 
by high-vacuum drying overnight. Three lipid films were then hydrated for a period of 30 minutes each at the 
temperature of 60 °C, with the corresponding buffer: A - 0.1 vol % NTG, B - 0.9 vol % saline, C - 0.1 vol % NTG. 
Afterwards, the liposomal suspensions were subjected to ten freeze-thaw cycles: frozen in liquid nitrogen and thawed in 
a 60 °C water bath. The liposomes were sized by multiple extrusions through Nuclepore™ track-etched polycarbonate 
membrane filters (Whatman, GE Healthcare Life Sciences, UK) of pore sizes of 400, 200, and 100 nm diameter pore 
sizes, until their diameter distribution became almost monodisperse. Multiple extrusions were performed using a barrel 
extruder Liposofast LF-50 (Avestin Inc., Canada) at 50 bar N2 pressure and a temperature of 65 °C. The samples loaded 
with Perlinganit were purified from excess of external NTG by buffer exchange using PD-10 desalting columns (GE 
Healthcare Bio-Sciences AB, Sweden), with an exclusion limit of 5,000 Da, following the manufacturer’s gravity 
protocol. The samples were stored at room temperature until use. To reach the human therapeutic dose (HTD) of 
encapsulated nitroglycerin each liposomal formulation (A, B, C) was diluted ten times (A*, B*, C*) before in vitro 
testing (cf. section 3.2). 
2.3 Characterization of lentil-shaped Pad-PC-Pad liposomes 
Measurement of size and size distribution 
The size and size distribution (polydispersity index, PDI) of the obtained liposomes was determined by triplicate 
measurements of each sample with the dynamic light scattering (DLS) technique using a DelsaNano C instrument 
(Beckman Coulter, USA) at a temperature of 25 °C. Measurements were performed on freshly prepared samples. The 
average diameter of the liposomes within each sample and standard deviations were calculated using the Smoluchowski 
model (see Table 1 below). The liposome stability over time was tested after 10, 30 and 60 days subsequent to 
preparation (see Figure 4 below). 
Measurement of zeta potential 
The zeta (ζ) potential of the samples was measured using the laser Doppler electrophoresis technique on a Zetasizer 
Nano-ZS (Malvern Instruments Ltd., UK). Liposomes samples were freshly prepared and measured with the following 
specifications: 60 s sampling time; 0.8872 cP medium viscosity; 1.33 refractive index; 173° scattering angle, using non-
invasive backscatter optics; 25 °C temperature (see Table 1 below). Data were analyzed using the Zetasizer software 
supplemented with the device. The zeta potential values were calculated using the Helmholtz–Smoluchowski's equation. 
Measurement of size and morphology 
Liposomes size and morphology were analyzed using transmission electron microscopy (TEM), using CM-100 electron 
microscope (Philips, Eindhoven, Netherlands), operating at an accelerating voltage of 80 kV. Samples were prepared by 
liposome deposition onto a 400-mesh carbon/palladium-coated copper grid (Polysciences Inc., Eppelheim, Germany), 
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substrate solution was added to each test well. Then, another incubation followed with a duration of 30 minutes (C4d) 
and 15 minutes (Bb), respectively, was done. After the incubation, the enzyme reaction was stopped chemically by 
adding 100 μL of EDTA stop solution. The optical density of the wells in each kit was measured spectrophotometrically 
with a plate reader at wavelengths of 405 (C4d) and 450 nm (Bb). 
Terminal complement complex (TCC) 
The level of the SC5b-9 complex was evaluated by MicroVue SC5b-9 Plus ELISA kit. The ELISA assay was carried out 
according to manufacturer’s instructions. Briefly, the assay wells were incubated with wash solution for a period of one 
to two minutes at a temperature between 15 and 20 °C. The samples’ aliquot of 100 μL and standards, in the 
concentration range from 0 to 185 ng/mL, were incubated in hydrated micro-assay plates for a duration of 60 minutes at 
room temperature. After incubation, the wells were washed with buffer for five times and 50 μL of HRP-conjugate was 
added to each test well. After incubation for 30 minutes at room temperature, the wells were washed with buffer for five 
times, and 100 μL of substrate solution was added to each test well. Afterwards, another incubation for a period of 
15 minutes took place. Then the enzyme reaction was stopped chemically by adding 100 μL of stop solution. The optical 
density of the wells in each kit was measured spectrophotometrically with a 96-well-plate plate reader (FLUOstar 
Omega, BMG Labtech, Germany) at wavelength of 450 nm.  
2.5 Statistical analysis 
The levels of SC5b-9, C4d and Bb in serum are expressed as mean ± S.D. For data analysis, all samples were compared 
to saline, except Zymosan. Significance of differences between the groups was determined by ordinary one-way analysis 
of variance (ANOVA), followed by Dunnett’s multiple comparison test. Differences between groups were considered 
statistically significant at P ≤ 0.05. Statistical analysis was carried out using GraphPad Prism 6 (GraphPad Software Inc., 
CA, USA). 
3. RESULTS 
3.1 Characteristics of shear-stress-sensitive Pad-PC-Pad liposomes 
Analysis of size and size distribution 
The DLS results indicate the mean diameter of the liposomes containing 5 mol% DSPE-PEG2000 corresponded to 115 nm 
(B) and 130 nm (A), while the average size of formulation composed of Pad-PC-Pad only – was above 2.5 µm (see Table 
1). The liposome stability was tested over 60 days after sample preparation. The related results are shown in Figure 4. 
Figure 4 A-B demonstrate the presence of only one peak in A and B samples after 60 days, while C shows the presence 
of three peaks. The two peaks at around 3 and 30 µm as well as the broad size distribution reveal the formation of 
liposomal aggregates. This was reflected in the PDI value, confirming that the sample was poly-disperse. 
Analysis of zeta potential 
The zeta potential was in the range from - 0.4 to + 3.1 mV (see Table 1). These values indicate that Pad-PC-Pad 
phospholipids are neutral and should exhibit a relatively low aggregation stability. 
Table 1. Properties of liposomal formulations tested in this study. Lipid concentrations of each suspension were determined 
by the phosphate test 2.0 and shown as the mean of three repeated measurements ± the relative error. DLS, PDI and ζ-
potential values were given as the mean ± standard deviation of a triplicate measurement. 
Name Lipid composition 
Lipid content 
(mg/mL) 
Average size (nm) PDI ζ-potential (mV) 
A Pad-PC-Pad/DSPE-PEG2000 8.19 ± 0.95 130.8 ± 3.7 0.10 ± 0.01 - 0.42 ± 0.4 
B Pad-PC-Pad/DSPE-PEG2000 9.18 ± 1.15 115.7 ± 0.7 0.08 ± 0.01 + 1.26 ± 0.45 
C Pad-PC-Pad 10.28 ± 0.40 2659.3 ± 247.4 0.91 ± 0.11 + 3.10 ± 0.16 
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lower count of vesicles analyzed via TEM. It should be noted that TEM analysis is a suboptimal tool to visualize 
liposomal formulations. In order to preserve initial morphology, and visualize liposomes in their native fully hydrated 
state, further imaging with a cryo-TEM is desirable. 
Human therapeutic dose of NTG 
The dosage of NTG should be adapted to the individual needs of the patient and to the response of controlled parameters, 
and the respective situation. The clinical dosage range is from 33 to 133 µg per minute [23]. Higher doses of 166 µg per 
minute are possible in rare cases [23]. In general, the results of treating acute hypertensive heart failure with intravenous 
bolus injection of 1 mg/mL of nitroglycerin were reported [24], as well as patients with severe decompensated heart 
failure with a bolus injection of 2 mg nitroglycerin [25] has been reported. Based on values obtained with the phosphate 
test for lipid concentration (Table 1), the encapsulated volume of NTG was calculated (cf. section 3.2). The quantity of 
nitroglycerin encapsulated in 10 mg/mL is about 391 µg, which is three times higher than the maximum dose. Therefore, 
a ten-fold dilution of each liposomal formulation was prepared and labeled as A*, B* and C*. Phospholipid content and 
encapsulated volume of NTG for these samples was calculated as ten times lower than initial one. However, the loading 
procedure of NTG into the liposomes was not optimized and the loading efficiency here certainly lies significantly lower 
than 100 %. 
In vitro determination of complement activation 
Overall, the level of C4d measured in all samples has shown low concentration of the protein, providing an evidence that 
complement activation of liposomes does not involve neither classical nor lectin pathways, at least to a major extent. 
Therefore, as the next step, the complement activation via alternative pathway was studied. We observed elevated levels 
of Bb concentration, caused by all the samples. This might be an indication that mainly the alternative pathway is 
involved in complement activation, caused by liposomal formulation. It was reported that increased Bb concentration in 
Doxil-sensitive sera, provides an evidence of its role in alternative pathway activation [26]. Abelcet has shown high 
activation of Bb protein, indicating a significant statistical difference. Abelcet is formulated from 1,2-dimyristoyl-sn-
glycero-3-phosphorylcholine (DMPC) and 1,2-dimyristoyl-sn-glycero-3-phosphorylglycerol sodium salt (DMPG), 
containing amphotericin B, as active drug. A major difference between Abelcet and the rest of the samples is the shape 
and size of the particles, which could serve as a recognition factor for initiation of the complement activation. It consists 
of ribbon-like complexes, with size of 1.6 to 11.0 μm. We expected also high values of protein activation by Zymosan in 
the Bb kit, since it is an activator of the alternative pathway. The amount of Zymosan-activated protein increased and 
multiplied along the activation cascade.  
Activation of TCC was represented by the concentration of the soluble C5b-9 protein complex, formed in human sera, 
after incubation with defined samples. The obtained values were normalized to the liposome concentration of 10 mg/mL 
(A, B, C) and 1 mg/mL (A*, B*, C*). This step was applied in order to improve data integrity and better differentiate the 
impact of the liposomal formulation upon the complement activation. Also, this helps to avoid misinterpretation of 
results due to higher or lower amounts of phospholipids within the sample. 
The results of Figure 7 indicate that formulations A and C induce relatively strong complement activation. However, 
some studies suggest that if the complement activation was detected in vitro, does not necessarily mean that a patient will 
also develop HSRs in vivo. Only those with more than five- to ten-fold increased protein level may carry a risk of 
complement activation and related HSRs [27]. Such alignment of the results of A and C samples may be caused by the 
presence of NTG within the vesicles, particularly, by combination of Pad-PC-Pad loaded with NTG. Additionally, under 
the conditions used, the Pad-PC-Pad vesicles were incubated above their main transition temperature, which should lead 
to a full release of the entrapped NTG. However, when alone, NTG does not cause detectable immune reaction. Similar 
situation results were obtained for Doxil, that in the presence of doxorubicin influences the activation of the complement 
system [26]. Van den Hoven reported that prednisolone sodium phosphate encapsulated within the liposomal aqueous 
interior also causes increased chance of complement activation [28]. Besides, our recent study demonstrates that drug-
free Pad-PC-Pad do not show any significant complement activation [22], as compared to their NTD-loaded liposomal 
counterparts. As follows, incorporation of certain drugs can cause physicochemical changes to the liposomal 
formulation, carrying a risk of elevated SC5b-9 concentration. Increased levels of complement activation by C sample 
can also be correlated with the presence of aggregates, that was confirmed by the DLS measurements. As can be seen 
from the results in Figure 7, no significant changes in complement activation were seen in the sample B, which contains 
PEG2000 coupled to DSPE. Sample B showed the lowest value of SC5b-9 concentration among three concentrated 
samples, and its value was comparable to the negative control. This result was compared with our previously reported 
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data, where Pad-PC-Pad liposomes loaded with PBS did not reveal complement activation after a period of 60 minutes of 
incubation [22]. Van den Hoven also suggests that PEGylated liposomal formulations carry a low risk for causing 
hypersensitivity reactions [28]. Besides, neither reduction of PEG chain length, nor decrease of PEG density at the 
liposome surface, significantly changes activation of complement system. However, Chanan-Khan and Szebeni both 
reported that PEGylated liposomal products, such as Doxil, can induce complement activation-related hypersensitivity 
reactions [26, 27]. However, not all the patients with complement activation displayed HSRs. As explained by Chanan-
Khan, it may be related due to the involvement of certain factors, which can limit adverse consequences of activated 
complement peptides, released during complement activation [27]. The TCC activator Zymosan induces complement 
activation immediately and after 40 minutes of incubation and has reached up to 62-fold higher SC5b-9 concentration as 
compared to saline. It shall be mentioned that for this experiment one donor was found to be consistently more sensitive 
than the others. This individual could be prone to complement activation and contributes to significantly larger values 
towards the average (e.g. by factor of two for the A*, B*, C*). It is known that all types of liposomes can cause 
complement activation, which can be even enhanced due to variety of factors, such as positive or negative surface 
charge, increasing the size of liposomes, PEGylation of liposomes, presence of aggregates, presence of drugs in the 
extra-liposomal medium, high percentage (> 50 %) of cholesterol in the membrane, etc. [29]. It has been shown that 
PEGylated liposomes with 120 nm in diameter, composed of cholesterol, have shown significant increase in activation of 
Bb, indicating that size and presence of PEG molecules might be important for complement activation by triggering the 
alternative pathway [28]. Nevertheless, in our study we did not observe the effect of PEGylation on the complement 
cascade, neither in the pathway, nor in TCC tests. It is important to notice, that the type of molecule used for anchoring 
the PEG plays a certain role. In our case, we used DSPE, and not cholesterol. However, the liposomal aggregation in the 
C sample had its impact on the increased level of TCC formation. Similar statements about direct impact of the 
liposomal size, charge, and presence of PEG molecules on the complement activation, can be very subjective, as the type 
of formulation and phospholipid concentration can vary significantly from one liposomal formulation to another. To our 
knowledge, the complement system reactivity to the synthetic non-natural Pad-PC-Pad liposomes, loaded with 
nitroglycerin were reported for the first time, therefore a direct comparison with other researcher’s reports is 
complicated. 
5. CONCLUSIONS 
Liposomes can trigger initiation of both classical and alternative complement pathways. Based on the absence of 
significant changes in C4d level, involvement of the classical and lectin pathways can be excluded in the complement 
activation by Pad-PC-Pad liposomes. Instead, we observed increased levels of Bb protein, among all the samples that is 
an indicator of potential involvement of the alternative pathway. However, no statistical significance between our 
liposomal formulations and the negative control was found. Current preliminary results demonstrate C-activation after 40 
minutes of samples’ incubation. Further studies will incorporate detailed analysis of complement activation over time, at 
the various time points. Besides, determination of the SC5b-9 complex formation of NTG-loaded Pad-PC-Pad liposomes 
in porcine sera would provide additional meaningful information for future in vivo studies. 
In summary, our results indicate that nitroglycerin-loaded Pad-PC-Pad liposomes prepared of approximately 10 mg/mL 
phospholipids can carry an increased risk on hypersensitivity reaction. Nevertheless, their diluted counterparts 
demonstrate weak, biologically non-significant, complement activation only in some sensitive donors. Sensitivity for 
complement activation by liposomes is exhibited on an individual basis, suggesting that sensitive individuals could 
experience a hypersensitivity reaction. This warns about certain risk for infusion reactions of concentrated Pad-PC-Pad 
liposomes, loaded with nitroglycerin. However, as mentioned above, diluted liposomal formulations already contain 
sufficient HTD of the encapsulated drug. Therefore, the application of diluted Pad-PC-Pad liposomes is a promising 
formulation that deserves to be further investigated.  
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Abstract 
Liposomal drug delivery systems can protect pharmaceutical substances and control their release. 
Systemic administration of liposomes, however, often activate the innate immune system, resulting in 
hypersensitivity reactions. These pseudo-allergic reactions can be interpreted as activating the 
complement system. Complement activation destroys and eliminates foreign substances, either directly 
through opsonization and the formation of the membrane attack complex (MAC), or by activating 
leukocytes and initiating inflammatory responses via mediators, such as cytokines. In this study, we 
investigated the in vitro immune toxicity of the recently synthesized Rad-PC-Rad liposomes, analyzing 
the liposome-induced complement activation. In five human sera, Rad-PC-Rad liposomes did not 
induce activation, but in one serum high sensitivity via alternative pathway was detected. Such a 
behavior in adverse phenomena is characteristic for patient-to-patient variation and, thus, the number 
of donors should be in the order of hundreds rather than tens, hence the present study based on six 
donors is preliminary. In order to further prove the suitability of mechano-responsive Rad-PC-Rad 
liposomes for clinical trials, the production of pro-inflammatory cytokines was examined by human 
white blood cells. The concentrations of the pro-inflammatory cytokines, IL-6, IL-12p70, TNF- , and 
IL-1 , induced by Rad-PC-Rad liposomal formulations, incubated with whole blood samples, were 
smaller or comparable to PBS (negative control). Because of this favorable in vitro hemocompatibility, 
in vivo investigations using these mechano-responsive liposomes should be designed.i 
                                                      
1 License: CC BY-NC-SA 4.0 
2 *Corresponding author: phone +41 61 207 5430, bert.mueller@unibas.ch, Biomaterials Science Center, Department of 
Biomedical Engineering, University of Basel, Gewerbestrasse 14, 4123 Allschwil, Switzerland 
Graphical Abstract: The 
mechano-responsive Rad-PC-
Rad liposomes, designed to 
deliver a vasodilator drug to 
stenosis, are stable even at 
elevated body temperatures. 
The question is whether these 
nano-containers with a 
specific shape present adverse 
effects similar to liposomal 
drugs in vitro or they don’t. 
26 2 Results
Precisionnanomedicine.com DOI: 10.29016/180419.2   @2018 Andover House, Andover, MA USA  
 The official Journal of CLINAM 
44 
Keywords 
Nanomedicines, non-spherical liposomes, immune toxicity, complement activation, hypersensitivity 
reactions, pro-inflammatory cytokines 
 
Purpose and Rationale 
The artificial diamidophospholipid Rad-PC-
Rad has been synthesized recently [1]. Rad-PC-
Rad liposomes aim to preferentially deliver the 
vasodilator molecules to the stenosed parts of 
blood vessels. Liposomes, administered 
intravenously, are immediately exposed to a 
complex environment of blood cells and 
proteins. The adsorption of plasma proteins on 
the surface of liposomes may not only decrease 
the therapeutic efficiency and biodistribution, 
but also may result in immunotoxicity. The 
toxicities which represent the most common 
safety issues and reasons for nanomedicines 
failure include complement-mediated reactions 
and cytokine-mediated inflammation, which 
can result in anaphylaxis. Therefore, in this 
study we investigated complement activation 
and release of pro-inflammatory cytokines, 
mediated by Rad-PC-Rad liposomes. The 
immunotoxicity can be also influenced by the 
therapeutic payload or addition of surface 
ligands. Therefore, the comparison between 
nitroglycerin-loaded and drug-free liposomes, 
as well as PEGylated and non-PEGylated 
liposomes was evaluated. The physicochemical 
properties of nanomedicines are crucial to 
determine their interaction with the immune 
system. Hence, we characterized the size, zeta 
potential, and phospholipid concentration of the 
Rad-PC-Rad liposomes. 
Introduction 
The latest progress in the nanomedicine field 
has resulted in the development of smart nano-
containers for drug delivery applications, 
including liposomes. Liposomes can improve 
delivery, targeting, and therapeutic efficacy of 
the drug and, at the same time, increase the half-
life of the drug, lower its effective dose, and 
reduce toxic side effects [2, 3]. Previously, our 
research team reported on shear stress sensitive 
Pad-PC-Pad liposomes for targeted delivery of 
a vasodilator to constricted arteries [4, 5]. A 
further in vivo investigation of Pad-PC-Pad 
phospholipids was limited owing to their phase 
transition temperature at 37 o C. Very recently, 
we have reported on a more thermally stable 
phospholipid formulation, such as Rad-PC-Rad 
[1]. This lipid exhibits a bilayer main phase 
transition temperature of 44.7 C and preserves 
the responsiveness for mechanical triggers [1]. 
The immediate treatment of arterial occlusion 
generally involves intravenous injection of 
nitroglycerin (NTG), which acts as a 
vasodilator. Systemic administration of NTG 
may cause severe adverse effects including 
hypotension and diminished blood perfusion to 
the heart. The targeted delivery of NTG via the 
incorporation into shear stress sensitive 
liposomes may reduce these side effects. The 
direct contact of liposomes with blood carries 
the risk of immediate activation of the innate 
immune system [6]. This may result not only in 
the reduction of the drug’  s efficacy, but also 
in the appearance of hypersensitivity reactions 
(HSRs) [6-8]. The main function of the immune 
system is to protect the organism from invading 
pathogens. It can, however, also develop an 
immune response against non-pathogenic 
objects, such as nanometer-size liposomes. 
Therein, the recruitment of the complement 
system is an important step in the recognition 
and elimination of foreign materials. The 
complement system is a group of 
approximately 30 plasma- and membrane-
bound proteins [9]. Their protective function 
leads to the release of active components, which 
cause opsonization, inflammation, and the 
generation of the membrane attack complex 
(MAC) [10]. According to the current literature, 
the complement activation occurs via the three 
established routes: classical, lectin, and 
alternative pathways [10]. One can discriminate 
between these pathways by identifying the 
presence of unique protein fragments: C4d 
(classical and lectin pathways) and Bb 
(alternative pathway) [11]. Activation of either 
pathway results in the turnover of the C3 
protein, which is followed by the production of 
the anaphylatoxins C3a and C5a, and the 
formation of the MAC (C5b-9). The release of 
anaphylatoxins causes leukocyte chemotaxis 
and the production of pro-inflammatory 
cytokines, which finally induce inflammation 
(Figure 1). The excessive production of 
anaphylatoxins can be harmful and may cause 
anaphylactic shock or even organ failure at 
relevant concentrations [12]. Binding of the 
proteins to the liposomes depends also on their 
composition, size, geometry, surface charge, 
and hydrophobicity that can act as 
immunological adjuvant and trigger strong 
immune response [6, 13]. The undesirable 
activation of the complement system can be 
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caused by systemically administered liposomes, 
such as Doxil® (PEGylated liposomal 
doxorubicin) and AmBisome® (liposomal 
amphotericin B), leading to the development of 
HSRs, termed complement activation-related 
pseudoallergy (CARPA) [7, 8]. Approximately 
2 – 10% of patients may adversely react to 
intravenously administered liposomal 
formulations with mild-to-severe 
hypersensitivity reactions [8]. CARPA 
develops at the first exposure and its symptoms 
involve almost all organ systems [14]. Some of 
the most important safety concerns for 
nanoparticle failure are related to the toxicities 
caused by complement activation-mediated 
reactions and cytokine-mediated inflammation 
[15]. Therefore, it is recommended that 
liposomes intended for intravenous injection 
are tested in vitro and in vivo for the potential 
activation of complement system, as a 
preclinical immune toxicity test [16]. The 
assessment of the liposomal physicochemical 
properties and their impact on complement 
activation is also an important objective in the 
development of nanometer-size therapeutics. 
The production of pro-inflammatory cytokines 
in vitro is considered a marker of cytokine-
associated immunotoxicity in vivo [15] and 
screening for these toxicities early in preclinical 
characterization will help to avoid potentially 
toxic candidates in nanomedicine development. 
Recently, Wolf-Grosse et al. reported about 
cytokine secretion in a complement-dependent 
manner [17]. They state that cytokine response 
was generally mostly due to C5a activation, as 
it is the most potent pro-inflammatory mediator 
released upon C activation [17]. Therefore, in 
order to prevent the potential immunotoxicity 
in vivo, we studied the effect of Rad-PC-Rad 
liposomes on the production of complement 
proteins and pro-inflammatory cytokines. 
Experimental design 
In the present article, we address the 
possibilities that Rad-PC-Rad liposomes, 
loaded with NTG solution, would activate the 
complement system and stimulate the release of 
pro-inflammatory cytokines, thus raising 
concern about potential risk for CARPA or 
cytokine storm. Thus, we have measured in 
vitro complement activation in human sera and 
the release of the pro-inflammatory cytokines, 
in human whole blood and isolated leukocytes, 
upon incubation with Rad-PC-Rad liposomes. 
The complement pathway activation products 
C4d and Bb, and terminal complement complex 
SC5b-9 were measured using an enzyme linked 
immunosorbent assay (ELISA), and the release 
of the pro-inflammatory cytokines IL-1, IL-6, 
IL-8, IL-12, TNF-α  was measured using a 
cytometric bead array test. In addition, we 
analyzed the liposomal physicochemical 
properties, in terms of liposomes size and zeta 
potential, using dynamic light scattering (DLS), 
and estimated membrane thickness from the 
micrographs, obtained by cryogenic 
transmission electron microscopy (cryo-TEM). 
Materials and Methods 
Materials 
1,3-Diheptadecanamidopropan-2-yl (2-
[trimethylammonio]ethyl) phosphate (Rad-PC-
Rad) was synthesized and purified according to 
the recently reported protocol [1]. Figure 2 
shows the structural formula of the Rad-PC-
Rad phospholipid. Table S1 lists all the 
materials used for the experiments. 
Human sera from six healthy volunteers and 
whole blood samples from two healthy donors 
were obtained through an institutionally 
approved phlebotomy protocol at Semmelweis 
University (Budapest, Hungary). Human sera 
were stored at a temperature of −80 °C until 
usage. Whole blood samples were freshly 
collected into sterile hirudin-treated tubes and 
immediately employed for experiment. Freshly 
drawn blood, used for leukocytes isolation, was 
provided by the Hungarian National Blood 
Transfusion Service.
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Figure 1. Schematic representation of complement (C) activation triggering pro-inflammatory cytokines due to anaphylatoxin 
binding to anaphylatoxin-receptor positive cells (e.g., mast cells, basophils, neutrophils, platelets and pulmonary 
intravascular macrophages). In the case of Rad-PC-Rad liposomes, C activation proceeds through the alternative pathway. 
On this pathway C3 directly binds to liposomal phospholipid head-groups. Factor B binds to the newly attached C3b, and 
again becomes susceptible to cleavage by factor D. Membrane-bound C3bBb is unstable until it is bound by properdin protein 
(factor P). Stabilized C3-convertase rapidly generates large amounts of C3b that bind more factor B, resulting in dramatic 
amplification of C3b. Membrane-bound C3b serves as an opsonin and a binding tag for phagocytic cells. Addition of C3b to 
C3-convertase results in the formation of C5-convertase, which cleaves C5 into C5b, and proceeds to form the MAC. Cleavage 
of C5 also results in the formation of C5a anaphylatoxin. Together with C3a, the C5a fragment binds to the surface C receptors 
of mentioned allergy mediating cells. C3a and C5a receptors, after binding small anaphylatoxins, mediate the allergic reaction 
by stimulating the release of vasoactive mediators (e.g., histamine, thromboxanes, leukotrienes, etc.). 
Liposome preparation 
Four Rad-PC-Rad/DSPE-PEG2000 phospho-
lipid formulations were prepared, namely R1, 
R2, R3, and R4 (see Table 1). Lipids were 
dissolved in chloroform in molar ratios as listed 
in Table 1. The preparation of the liposomal 
formulations is described in detail in ref. [18]. 
The samples were purified through sterile 
filters and stored at a temperature of 4 C until 
usage. 
Characterization of liposomal 
formulations 
Phospholipid concentration. A colorimetric 
assay (phosphate test 2.0) [19] was used for the 
determination of the phospholipid content of 
the liposomal formulations after extrusion and 
purification. Here, the phosphate moiety in the 
head group of the phospholipids was a measure 
of the total phospholipid concentration. 
Table 1. Composition of Rad-PC-Rad 
liposomal formulations 
Label 
Lipid composition 
(molar %) Loading 
buffer Rad-PC-
Rad 
DSPE-
PEG2000 
R1 100 - saline 
R2 95 5 saline 
R3 100 - NTG 
R4 95 5 NTG 
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To exclude the variations in lipid concentration, 
the concentration of each liposomal 
formulation (R1, R2, R3, and R4) was diluted 
with 0.9% sodium chloride solution (saline) to 
a total lipid concentration of 10 mg/mL. In 
addition, a set of the diluted formulations (R1d, 
R2d, R3d, and R4d) with 5 mg/mL of 
phospholipids were prepared for the in vitro 
immunoassays to examine the impact of the 
lipid concentration on the complement 
activation level (see Figures S2 and S3).  
Physicochemical characteristics. The liposome 
average diameter, polydispersity index (PDI) 
and zeta () potential were obtained by DLS 
performed at a temperature of 25 C using a 
DelsaMax PRO (Beckman Coulter, USA). The 
suspensions were diluted 100 times in saline 
prior to the measurements. 
Liposome morphology. The morphology of four 
Rad-PC-Rad formulations was studied using 
cryogenic transmission electron microscopy 
(cryo-TEM) (JEM2200FS, JEOL, Tokyo, 
Japan). The samples, diluted with saline in the 
ratio 1:1, were imaged as previously reported [1, 
18]. 
Encapsulation efficiency. The encapsulation 
efficiency of Rad-PC-Rad liposomes for 
passive loading with nitroglycerin was 
determined indirectly by measuring the peak of 
a glucose-trifluoroacetic acid adduct by 
electrospray ionization mass spectrometry 
(ESI-MS) on a Bruker esquire HCT ion trap 
mass spectrometer (Bruker Corporation, USA) 
[18]. 
Liposomal release. Two Rad-PC-Rad 
liposomal formulations, i.e. with and without 
DSPE-PEG, were loaded with 5(6)-
carboxyfluorescein (CF) buffer, and prepared 
as described in ref. [1]. Seven aliquots with a 
volume of 2 mL were separated into 5 mL glass 
vials and kept for selected periods of time (0, 5, 
10, 20, 40 min) at a temperature of 37 C. The 
CF release was quantified using a 
fluorospectrometer (SpectraMax 2, Bucher 
Biotec AG, Switzerland) with the wavelengths 
of 485 nm for excitation and 538 nm for 
emission. Sample fluorescence at a temperature 
of 20 C served as a negative control (F0). As a 
positive control for the maximum dye release 
(F100), liposomal samples were heated to a 
temperature of 65 C, above the lipids 
transition temperature of 44.7 C. The release 
fraction at the selected time point x was 
calculated according to: 
𝑅𝑒𝑙𝑒𝑎𝑠𝑒(%) =
𝐹𝑥 − 𝐹0
𝐹100 − 𝐹0
 
where 𝐹𝑥 is the fluorescence at time x. 
Complement immunoassay 
Activation of human sera with liposomes. 
Human sera from six healthy donors were 
thawed and kept at a temperature of 4 °C 
during the experiment. Due to the limited 
amount of serum available, the sera #5 and #6 
were prepared as pools from distinctive donors 
in the ratios 1.5:1 and 7.8:1, respectively. The 
liposomal suspensions in the two 
concentrations were added to the sera of each 
donor in the ratio of 1:3. Saline and 
nitroglycerin were used as negative controls. 
FDA-approved liposomal drugs, with recorded 
cardio-toxicity effects and activation of the 
complement system in sensitive patients, 
Doxil® (2 mg/mL doxorubicin, 12.77 mg/mL 
phospholipids, used as provided) and 
AmBisome® (17.975 mg/mL amphotericin B, 
4.02 mg/mL phospholipids, reconstituted with 
injection water) were employed as well [7]. 
Zymosan (1.2 mg/mL), known as activator of 
the complement system, was used as positive 
control. Each activation mixture was incubated 
at a temperature of 37 °C. The concentration 
of the terminal complement complex SC5b-9 
was investigated over time. The incubation was 
terminated after 5, 10, 20, and 40 minutes by 
adding 10 mM EDTA. 
ELISA immunoassays 
The ELISA assays were carried out following 
the manufacturer ’ s protocol. The optical 
density was measured with a 96-well plate 
reader (FLUOstar Omega, BMG Labtech, 
Germany) at a wavelength of 450 nm for SC5b-
9, Bb, C3a and C5a as well as at a wavelength 
of 405 nm for C4d. 
Cytokine immunoassay 
Isolation of leukocytes from buffy coat. A 
volume of 400 mL of buffy coat (BC), a pool of 
white blood cells (WBCs) concentrates of four 
healthy volunteers, were obtained from the 
Hungarian National Blood Transfusion Service 
within 24 hours of blood withdrawal. 
Altogether three BC pools were used, each 
consisting of four donors. Leukocytes were 
further concentrated two times by mixing with 
DPBS (w/o CaCl2, MgCl2) in 1:1 ratio and 
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centrifuged for a period of ten minutes at a 
velocity of 750 G and a temperature of 4 °C. 
To lyse the remaining erythrocytes, distilled 
water at a temperature of 4 °C was added to 
the BC (4:1 ratio) for 20 seconds. Lysis was 
stopped by adding one volume hyperosmotic 
salt solution (containing 1.8% of NaCl). After 
washing with ice-cold DPBS (w/o CaCl2, 
MgCl2) for platelets elimination, WBCs were 
re-suspended in R5 medium. 
Qualitative and quantitative analysis of 
isolated leukocytes. The concentration of 
WBCs, in three independent blood packages 
was determined. Viable cells were detected 
using FITC Annexin V apoptosis detection kit, 
see Table S4. The staining procedure was 
performed according to the manufacturer’s 
instructions. Leukocytes were further diluted or 
concentrated to reach the necessary 
concentration of 108 cells/mL. The cell 
viability was also checked after cell isolation 
and treatments by test materials and control 
agents. The viability of cells before and after 
treatments were always higher than 98%, 
except for the positive control, Table S5. 
Activation of BC leukocytes with liposomes. 
Freshly isolated leukocytes from three 
independent blood packages were separately 
incubated with four Rad-PC-Rad liposomal 
formulations in the ratio 7:1. Samples, with a 
concentration of 4 mg/mL, were incubated for 
four hours at a temperature of 37 °C on a 
shaker plate. The incubation was stopped by 
EDTA (final concentration 10 mM). Cell 
culture supernatants were further used for 
mixing with cytokine capture beads. The assay 
was performed according to the suggested 
protocol the manufacturer provided with the kit. 
Activation of human whole blood with 
liposomes. Freshly collected whole human 
blood from two donors was separately 
incubated with four Rad-PC-Rad liposomal 
formulations at a concentration of 4 mg/mL, 
following the same procedure as described in 
the section above. The distinctive step was the 
incubation time. Here samples were incubated 
for a period of six hours. Whole blood samples 
had no R5 medium, instead they contained their 
own plasma. 
Qualitative and quantitative analysis of 
leukocytes originated from whole blood 
samples. An aliquot of human blood from two 
donors was stained as described in the section 
above. Cell viability was determined before and 
after treatments by test materials and control 
agents. The percentage of viable cells was more 
than 97%, except for the positive control, Table 
S5. 
Cytometric bead array test. The human 
inflammatory cytokines kit was used to 
quantitatively measure interleukin-1 (IL-), 
interleukin-6 (IL-6), interleukin-8 (IL-8), 
interleukin-12p70 (IL-12p70), tumor necrosis 
factor α (TNF-α), and interleukin-10 (IL-10) 
protein levels in the studied samples. The assay 
was carried out following the manufacturer’s 
instructions. The beads fluorescence was 
recorded by flow cytometry using a FACScan 
instrument (BD Biosciences, USA), and the 
data were analyzed using the Kaluza Analysis 
1.5 software (Beckman Coulter, USA). 
Statistical analysis 
Statistical analysis was carried out using 
GraphPad Prism 6 (GraphPad Software Inc., 
USA). Data from the ELISA samples (Figures 
4 and 7), except zymosan, were compared with 
saline as negative control after 40 minutes of 
incubation. Significance of differences between 
the groups was determined by non-parametric 
Kruskal-Wallis test, followed by Dunn's 
multiple comparisons test. P-values lower than 
0.05 were considered as statistically significant. 
Results 
Characterization of Rad-PC-Rad liposomal 
formulations 
The lipid concentration of Rad-PC-Rad ranged 
from 10 to 20 mg/mL, and the mean diameter 
of the liposomes in the suspensions was around 
100 nm and varied from 95 to 140 nm (see 
Table 2). Measurements after 20 days showed 
that the PEGylated liposomes did not change 
their size, whereas the non-PEGylated ones 
displayed an increase from 140 to 270 nm (R1) 
and from 115 to 200 nm (R3). 
Table 2 lists the measured zeta potential values 
of the Rad-PC-Rad formulations. Pure Rad-PC-
Rad samples revealed positive  potential 
values, between +1.3 (R1) to +4.7 mV (R3), 
while PEGylated samples turned to negative 
potentials, from −2.0 (R4) to −4.5 mV (R2).  
The size and morphology of Rad-PC-Rad 
liposomes, evaluated using cryo-TEM imaging, 
is represented in Figure 2. These micrographs 
show intact spherical, lenticular, and faceted 
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unilamellar liposomes below their main phase 
transition temperature. The percentage of 
faceted liposomes within samples was 46% 
(R1), 72% (R2), 42% (R3), and 52% (R4).
Table 2. Characteristics of Rad-PC-Rad liposomal formulations. 
Label 
Lipid 
composition 
Lipid 
content 
(mg/mL) 
Mean 
diameter 
(nm)* 
PDI* 
Membrane 
thickness 
(nm) 
 potential 
(mV)* 
R1 
Rad-PC-Rad 
(saline) 
10.17  0.02 138.6  3.5 0.15  0.03 3.27  0.14 +1.29  0.37 
R2 
Rad-PC-
Rad/DSPE-
PEG2000 (saline) 
18.39  0.13 106.5  1.9 0.14  0.02 3.60  0.21 −4.52  1.05 
R3 
Rad-PC-Rad 
(NTG) 
13.62  0.72 114.5  0.4 0.06  0.03 3.27  0.19 +4.65  0.42 
R4 
Rad-PC-
Rad/DSPE-
PEG2000 (NTG) 
21.75  3.35 97.0  0.6 0.12  0.01 3.50  0.24 −2.08  0.51 
* Data were recorded immediately after sample preparation. 
 
The addition of DSPE-PEG (see Figure 2D and 
2F), led to the co-existence of flat circular disks 
and unilamellar liposomes. Depending on the 
disk orientation, they appear either as small 
rods with high contrast (red-colored arrows), or, 
when seen from the top, as circular structures 
with low uniform contrast (Figure 2D, right). 
The liposome membrane thickness was 
estimated from the cryo-TEM projections of the 
appropriately oriented membranes (Figure 2). 
We have measured the individual thicknesses 
of 100 membranes and found the mean values 
of R1 to be (3.27 ± 0.14) nm and of R3 to be 
(3.27 ±  0.19) nm, which indicates the 
interdigitation of the Rad-PC-Rad leaflets. 
Interdigitation may be one of the driving forces 
in the formation of faceted liposomes [1]. 
Samples loaded with DSPE-PEG, i.e. R2 and 
R4, tended to result in higher mean values. The 
values correspond to (3.60 ±  0.21) nm and 
(3.50 ±  0.24) nm, respectively. The mean 
diameters of the liposomes, derived from cryo-
TEM images, were 10–15% smaller than those 
obtained from DLS data.  
The encapsulation efficiency of NTG-loaded 
samples was estimated from the ESI-MS 
measurements. The calculation is based on the 
100% ESI-MS signal of pure NTG and 
liposome size. The employed NTG solution 
contained glucose as an excipient, therefore, the 
NTG encapsulation was determined indirectly. 
The integral of the glucose-trifluoroacetic acid 
adduct was evaluated after NTG incorporation. 
The ratio between these values determines the 
percentage of NTG encapsulation efficiency 
(see Table S2). The values correspond to 38% 
(R3) and 12% (R4). 
In order to measure the membrane permeability, 
a release test of CF-loaded liposomes at a 
temperature of 37 °C was performed under 
static conditions (Figure 3). Both, Rad-PC-Rad 
and Rad-PC-Rad/DSPE-PEG samples 
demonstrated an immediate spontaneous 
release of 17% and 8% CF, respectively. 
During another 40 minutes of incubation the 
release level increased to 36% (Rad-PC-Rad) 
and 33% (Rad-PC-Rad/DSPE-PEG). The initial 
CF release trend line of both samples was 
distinctive, however after 25 minutes the 
spontaneous release level of the two 
formulations was comparable and reached 
about 35%. 
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Figure 2. The structure of the two phospholipids used for the liposome preparation: Rad-PC-Rad (A) and DSPE-PEG (B). 
Cryo-TEM micrographs of the liposomal formulations: R1 (C), R2 (D), R3 (E), R4 (F). Scale bars are 100 nm. The samples 
contain spherical and faceted liposomes. The incorporation of DSPE-PEG caused the formation of bicelles indicated by the 
red-colored arrows. 
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Figure 3. The release of 5(6)-carboxyfluorescein 
containing liposomes formulated from Rad-PC-Rad and 
Rad-PC-Rad/DSPE-PEG. The samples were heated to a 
temperature of 37 °C and kept at constant temperature 
for a period of 0, 5, 10, 20, and 40 minutes. The final 
spontaneous CF release was about 35%. The data are 
represented as mean values, error bars indicate standard 
deviation (n = 5). 
Complement immunoassays 
Figure 4A displays the level of SC5b-9 (TCC), 
which is a marker for the activation of the 
complement system. The mean values of the six 
donors demonstrate that the liposomal 
formulations R1 and R3 have caused an eleven- 
and 15-fold increase in SC5b-9 concentration in 
comparison to the negative control (saline), 
whereas R2 and R4 have raised the SC5b-9 
concentration by a factor of eight or nine, 
respectively. Noticeably, Donor #5 (gray 
hexagonal) showed a tremendous increase of 
TCC in the four Rad-PC-Rad liposomal 
formulations, which largely contributed to the 
increased mean values of each liposomal 
sample. The increase of SC5b-9 was at the same 
level with its positive control, namely about 28-
fold compared with saline (Table S3). Certainly, 
the contribution of Donor #5 into the mean 
value of all six donors, caused a deviation of 
mean values up to four times. Doxil® and 
AmBisome® samples did not reveal a 
substantial difference in the level of SC5b-9 
between the six donors. Doxil® samples showed 
less than two-fold increase, while AmBisome® 
demonstrated more than nine-fold elevation of 
the TCC protein compared to saline. Zymosan 
caused a considerably high level of 
complement activation, namely 55-fold, and 
was excluded from the diagrams to present the 
differences between the tested samples in a 
clearer way. Our findings were statistically 
confirmed. NTG, which was chosen as another 
negative control, was compared to saline and no 
statistical difference was identified. R1 and R3 
samples showed very significant to extremely 
significant differences compared to the 
negative control. In contrast, the samples R2 
and R4 did not reveal a statistically significant 
difference versus saline. The SC5b-9 level 
caused by Doxil® among the six sera, showed 
no statistical difference compared to saline. 
Certainly, AmBisome® was detected to be 
extremely significant towards the negative 
control. 
Figure 4B demonstrates the level of C4d protein, 
which is an experimental marker for the 
activation of the classical and the lectin 
pathways. Neither the Rad-PC-Rad liposomes, 
nor the FDA-approved liposomal formulations 
revealed a significant increase of C4d protein 
concentration. The mean values show a less 
than four-fold increase in comparison to the 
negative control. 
Figure 4C represents the level of Bb fragment 
as an experimental marker for alternative 
complement system activation. The serum from 
Donor #5 towards Rad-PC-Rad liposomal 
formulation showed four to eight-fold elevation 
of Bb concentration, whereas the other five 
donors demonstrated less than three-fold 
increase compared to saline. All six sera were 
similarly sensitive to the AmBisome® with an 
increase of four times above the negative 
control, revealing a strong statistical 
significance. A significant serum reactivity 
towards Doxil® was not observed. 
The detection of C3a (Figure 4D) revealed no 
significant difference between the highly 
sensitive donor and the others. Most of the 
values were within the error bars. Rad-PC-Rad 
liposomes and Doxil® showed values between 
two- and three-times higher in comparison to 
saline, while AmBisome® caused an elevation 
of C3a similar to that one of the positive control 
– a three- to four-fold increase. 
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Figure 4. The concentration of SC5b-9 (A), C4d(B), Bb (C), C3a (D), and C5a (E) complement proteins. Human sera from six 
independent donors were incubated for a period of 40 minutes at a temperature of 37 °C with saline, nitroglycerin (NTG), 
Rad-PC-Rad liposomal suspension of selected composition (R1, R2, R3, R4), Doxil® and AmBisome®. Saline solution was 
chosen as negative control. NTG was used as another negative control. Non-PEGylated liposomal formulations caused a 
higher level of C activation, mainly via the alternative pathway. Highly sensitive serum towards artificial Rad-PC-Rad 
liposomes was identified. This activation of the C cascade resulted in the increased production of C5a anaphylatoxin. The 
positive control zymosan caused substantially higher levels of complement activation. The data are represented as median, 
including error bars derived from the interquartile range among six donors. Each symbol and color represents data from a 
single donor. Significance of differences among the groups was determined by non-parametric Kruskal-Wallis test, followed 
by Dunn's multiple comparisons test. P-values lower than 0.05 were considered as statistically significant.
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Figure 5. Concentration of pro-inflammatory cytokines IL-6 (A), IL-12p70 (B), TNF-α (C), and IL-1 (D) induced by Rad-
PC-Rad liposomal formulations (R1-R4) incubated with whole blood samples from two donors (first donor: left panels, second 
donor: right panels) for a period of six hours at a temperature of 37 °C. PBS was chosen as negative control. The effect of 
Rad-PC-Rad liposomes upon production of cytokines was lower or comparable to the negative control. Less than two-fold 
increase in the IL-12p70 concentration was observed by R1 treatment (first blood sample). The second blood sample revealed 
a highly elevated concentration of IL-12p70 induced by R2. IL-1 concentration of the second donor’s blood was close to 
the detection limit of the kit. The positive control zymosan caused a considerably high level of complement activation, which 
was mostly above the top standard concentration and was therefore excluded from the graph. The data represent a single 
value from each donor. 
For the activation of SC5b-9, Bb, and C3a, 
Donor #5 demonstrated a similar trend, where 
the reactivity towards Rad-PC-Rad samples 
was higher for the R1 and R3 samples 
compared to R2 and R4. 
Donor #5 showed a significant increase in C5a 
concentration in comparison to the other five 
donors (Figure 4E). The values were elevated 
17- to 21-fold above the negative control, and 
the trend was distinctive from the one 
previously observed (SC5b-9, Bb and C3a). 
Here, sample R2 revealed the highest C5a level, 
whereas R1, R3 and R4 were similar. The 
increase of the C5a concentration detected by 
the other five donors was below four times the 
baseline for the Rad-PC-Rad samples and 
Doxil®, while AmBisome® displayed a four-
fold increase 
Cytokine immunoassay 
The concentration of the inflammatory 
cytokines is listed in Table S6: IL-6, IL-12p70, 
TNF-α, IL-1, IL-10 and IL-8. Figures 5 and 
6 represent the levels of the identified pro-
inflammatory cytokines in whole blood and BC 
cells, respectively, caused by Rad-PC-Rad 
liposomal formulations. 
The concentration of each cytokine was 
compared to saline, which served as a negative 
control. Whole blood samples were collected 
from two donors and revealed a substantial 
difference in the sensitivity towards the studied 
samples. The effect of Rad-PC-Rad liposomal 
formulations on the production of pro-
inflammatory cytokines were lower or 
comparable to the negative control. Less than a 
two-fold increase in the cytokine concentration 
was caused by R1 and R4 samples, in case of 
IL-12p70 (first blood sample) and IL-1 
(second blood sample), respectively, see 
diagrams in Figure 5B and 5D. The 
concentration of IL-1 (second blood sample) 
was below the detection limit of the kit (see 
Table S6). Surprisingly, the second donor 
showed a large increase in production of IL-
12p70 in response to the R2 sample, even 
higher than the positive control. However, as no 
additional donor samples were available, we 
cannot conclude the importance of this increase.
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Figure 6. Concentration of pro-inflammatory cytokines induced by Rad-PC-Rad liposomal formulations incubated with 
isolated leukocytes from three buffy coat pools, each consisting of four donors. Buffy coats were incubated with R1-R4 for a 
period of four hours at a temperature of 37 °C. PBS was chosen as negative control. The Rad-PC-Rad formulations caused 
an elevated level of IL-6 in a part of the buffy coat samples. Insubstantial elevation of IL-12p70 was identified in R2 treated 
group in each BC. The increase in the level of TNF-α was observed only in one of the buffy coats by R2 sample. The other 
Rad-PC-Rad liposomal formulations were comparable with PBS. The positive control zymosan caused a considerably higher 
level of complement activation, which was above the top standard concentration and was therefore excluded from the graph. 
The data represent a single value from each buffy coat. The label “nd” means not detected. 
 
The concentration of IL-10 was detected only 
in the samples treated with the positive control. 
The level of IL-8 gave false positive results and 
was above the top standard concentration, see 
Table S6. Therefore, it was excluded from the 
study. 
Rad-PC-Rad formulations caused an elevated 
level of IL-6, by four- to nine-fold, in one of 
three BCs compared to PBS (see Figure 6A). 
The concentration of IL-6 caused by R5 
medium, however, was comparable to the one 
caused by R1 and R4 (see Table S6). Another 
BC sample demonstrated an increased level of 
IL-6, caused only by the R1 sample. A raise in 
the IL-6 concentration caused by the third 
tested BC sample was not detected by any of the 
liposomal formulations (see Figure 6A). In case 
of IL-12p70, incubation with four Rad-PC-Rad 
formulations resulted in less than two-fold 
increase of the cytokine level (see Figure 6B). 
Moreover, in some of the cases, IL-12p70 
levels stimulated by Rad-PC-Rad liposomes 
were lower than those of the negative control. 
A surprising increase in the concentration of 
TNF-α was observed in one of the BC samples 
by R2 (Figure 6C). None of the other samples 
elicited an increase in the TNF-α cytokine. In 
case of IL-1, only R3 demonstrated a two-fold 
increase of the cytokine above the negative 
control (see Figure 6D) whereas the other Rad-
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PC-Rad liposomes revealed an increase of IL-
1 of less than a factor of two. In summary, the 
cytokines levels caused by Rad-PC-Rad 
liposomal formulations were comparable with 
those caused by the negative control. 
Discussion 
The objective of the study was to investigate the 
immune response towards the recently 
developed artificial Rad-PC-Rad liposomes 
loaded with NTG. For this purpose, we 
measured the level of C activation markers and 
pro-inflammatory cytokines in vitro. We 
performed the physicochemical 
characterization of Rad-PC-Rad liposomes and 
discussed their potential influence upon the 
activation of the immune system. 
Characterization of Rad-PC-Rad liposomal 
formulations 
The surface charge of Rad-PC-Rad liposomal 
suspensions was characterized using the ζ -
potential, which is one of the principal 
indicators of the colloid stability. A potential of 
±  30 mV has been considered as the limit, 
above which a colloidal system becomes stable 
[20]. Rad-PC-Rad liposomes are non-charged 
nanometer-sized species with relatively low 
repulsive forces. They tend to aggregate. To 
improve the stability of the Rad-PC-Rad 
liposomes, we incorporated DSPE-PEG 
molecules into the liposomes, which cause a 
steric repulsion between lipid bilayers [21]. 
Furthermore, it resulted in the alteration of the 
ζ-potential to negative values. This alteration 
is a consequence of the negatively charged 
DSPE-PEG molecules owing to its 
phosphodiester moiety [22]. 
The morphology of Rad-PC-Rad liposomes can 
deviate from the spherical shape. The 
liposomes often exhibit irregular facets (Figure 
2). The co-existing spherical and facetted 
liposomes are two forms that may differ in the 
molecular fraction of the lipid components. 
Therefore, we have performed differential 
scanning calorimetry and found that upon 
repeated heating and cooling additional peaks 
arose (see Figure S1). This observation clearly 
indicates that various phases have become 
coexistent. The occurrence of faceted 
liposomes is explained by the formation of an 
intermolecular hydrogen-bonding network at 
the hydrophobic-hydrophilic interface of the 
lipids and membrane interdigitation, as recently 
studied for Rad-PC-Rad in detail [1]. 
The PEG-containing liposomes, R2 and R4, 
sometimes appear as flat circular disks (see 
micrographs D and F in Figure 2). In fact, these 
features originated from tilted bicelles or 
micelles [23, 24]. It should be noted that DSPE-
PEG is known as a micelle-forming species [25, 
26]. The spontaneous formation of bicelles is 
related to the phase separation between Rad-
PC-Rad and DSPE-PEG. The formation of 
bicelles without an internal cavity led to the 
decrease of NTG encapsulation by 26%. This 
shortcoming has to be addressed in future 
investigations by balancing the PEG-
incorporation to optimize the liposomes ’ 
stability and minimize bicelles formation. 
The cobblestone-like features in the micrograph 
D of Figure 2 may originate from PEGylated 
lipids, which failed to form liposomes. The 
samples have to be frozen for the cryo-TEM 
data acquisition. The higher viscosity of 
PEGylated samples results in the formation of 
thick ice, which impedes the imaging, see 
micrographs D and F of Figure 2. 
Complement immunoassays 
We examined the biological effects of Rad-PC-
Rad liposomes on C activation. C activation by 
liposomes depends on several physicochemical 
factors, including lipid composition, liposome 
size, morphology, and surface charge [27-29]. 
Larger liposomes are more prone to activate the 
complement system than smaller liposomes 
[30]. This observation explains the increased 
level of C proteins by the R1 and R3 samples, 
which diameters were larger and increased with 
time owing to aggregation. The importance of 
geometric factors on the assembly of 
complement convertases [30] or provoking 
cardiopulmonary distress in pigs [31] can also 
be a pivotal parameter in combating adverse 
reactions. The impact of geometry and topology 
on complement activation was identified by 
Moghimi et al. and Wibroe et al. [28, 31]. The 
cryo-TEM images represented in Figure 2 show 
Rad-PC-Rad liposomes with faceted and 
spherical shapes as well as disk-like PEGylated 
phospholipid-based bicelles. Therefore, the 
study on adverse reactions of rod- and disk-like 
particles reported recently [31] is of particular 
value. Even though this study reports on C-
independent adverse injection reactions, it 
clearly demonstrates the impact of the particle 
morphology on the immune cells recognition. 
The incorporation of PEG into liposomes is 
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considered to improve C compatibility and 
prolong liposomes circulation [32]. Their 
infusion, however, can give rise to HSRs [7, 33, 
34]. PEGylated liposomes are able to trigger C 
activation due to the presence of the anionic 
phosphate-oxygen moiety of the PEGylated 
phospholipid [35]. Positive or negative surface 
charge may also enhance C activation [36], for 
example by insertion of the negatively charged 
PEGylated phospholipids. Such negative ζ -
potential values were identified in the PEG-
containing Rad-PC-Rad liposomal 
formulations. The C activation-promoting 
activity of negative surface charges on 
liposomes was already discussed previously [7]. 
In our study, only minor differences were 
observed in PEGylated samples versus negative 
control. 
Another interesting phenomenon was observed, 
when drug molecules were encapsulated into a 
liposomal cavity (e.g., Doxil®, prednisolone). 
The C activation was considerably higher than 
for the liposomes of the same size and 
composition but without the entrapped drug [32, 
37]. In case of Doxil®, this phenomenon was 
explained by changes in the liposomal 
morphology arising from the drug loading 
procedures [28]. Here, we observed that NTG-
containing samples (R3 and R4) caused a 
slightly increased level of C proteins, in 
comparison to their drug-free counterparts. 
NTG alone did not have any significant impact 
on C activation (P < 0.05). 
The release test showed that 17 – 36% of 
loaded buffer was spontaneously released 
during the incubation. These observations 
suggest that the drug incorporation into the 
liposomes causes physicochemical changes to 
the liposomal formulation. Together with a 
partial release of the drug it may have a 
synergistic effect on C activation. The 
frequency of HSRs from FDA-approved 
liposomal drugs varies, for example ~10% with 
Doxil® and ~30% with AmBisome® [7]. 
AmBisome®, a highly negatively charged 
liposome formulation, was found to be a very 
strong C activator [7]. AmBisome® 
significantly differs from Doxil®, which causes 
strong C activation only in certain sensitive sera. 
This feature was confirmed in our experiment. 
AmBisome® caused the formation of 
significantly higher (P < 0.05) levels of all C 
proteins (Figure 4). 
The increased level of TCC led us to determine 
the pathway of C activation. We found that the 
classical and lectin pathways were not involved 
in the C activation, but could confirm that the 
alternative pathway was involved, in agreement 
with previous results on Pad-PC-Pad liposomes 
[11]. 
It has to be noted that one of the six human sera 
showed an anomaly. This pooled serum, #5, 
was highly sensitive to the Rad-PC-Rad 
liposomes. Although the pooling of sera from 
different donors is common for in vitro studies, 
it should be handled with care and the ratio 
seems to play an important role: the volumes 
from each serum should be equal [38]. As this 
phenomenon has not been considered in the 
present study, the experimental data were 
evaluated excluding Donor #5 (see Figure 7). 
The differences between the sera provide 
evidence for the utility of in vitro C assays and 
mimic the clinical situation. HSRs are mostly 
minor and transient; however, life-threatening 
reactions can happen occasionally in a 
hypersensitive individual. It has been suggested 
that for those donated sera, which cause C 
activation more than four times the baseline 
level, the related human being has an elevated 
risk of HSRs development [33]. The mean level 
of SC5b-9, within four sera (for R2 and R4) was 
below four times baseline (saline) (see Figure 
4A). Therefore, one could expect that these 
donors do not carry a risk for developing 
hypersensitivity reactions in vivo. R1 and R3, 
however, showed a five- and eleven-fold 
increase in the SC5b-9 concentration, which 
means that non-PEGylated Rad-PC-Rad 
liposomes might trigger the development of 
HSRs in vivo. Our previous studies demonstrate 
that at high phospholipid concentration Pad-
PC-Pad liposomes induce weak to none 
complement activation in vitro, but no 
significant changes in the hemodynamic 
parameters, nor anaphylactic reactions were 
observed in vivo [18, 39]. 
The identification of the reactive Donor #5 
motivated further studies. Those studies 
showed that inflammatory mediators, such as 
C3a and C5a, became activated. The increased 
level of the anaphylatoxins potentially causes 
strong pro-inflammatory or anaphylactic 
responses [6, 10, 40]. Although the C3a 
concentration caused by Rad-PC-Rad 
liposomes was below three-fold the baseline 
level, the non-PEGylated liposomal samples 
were elevated significantly (P < 0.05). In 
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addition, the Rad-PC-Rad liposomes provoked 
C activation that resulted in an increased level 
of C5a anaphylatoxin. It is known that C3a and 
C5a are major contributors to the release of pro-
inflammatory cytokines [6, 9, 40]. These 
fragments serve as ligands for receptors on 
leukocytes that trigger inflammation and 
release of pro-inflammatory cytokines, 
including IL-1β, TNF-α, IL-6 and the highly 
potent chemokine IL-8 [9]. The activation of 
leukocytes with C3a and C5a is the most 
relevant property of these proteins for immune 
compatibility. C5a induces degranulation, 
chemoattraction and acts with IL-1 and TNF-
α to induce an acute immune response [10]. 
Recently, a direct link between C activation and 
the secretion of cytokines, caused by iron 
nanoparticles was presented [17]. Therefore, to 
prevent any other potential immunotoxicity in 
vivo, we studied the effect of Rad-PC-Rad 
liposomes on the production of pro-
inflammatory cytokines. 
Cytokine immunoassay 
The identification of a highly reactive donor to 
Rad-PC-Rad liposomes, as demonstrated by a 
consistently and significantly higher level of 
complement proteins and C5a anaphylatoxin 
prompted us to investigate the pro-
inflammatory response to Rad-PC-Rad. 
Measuring the cytokine release allows 
estimating the inflammatory properties of the 
tested species. To quantify the impact of Rad-
PC-Rad liposomes on cytokines’ production, 
we used isolated leukocytes and human whole 
blood. Our results obtained with whole blood 
showed differences between the two donors. 
Multiple factors have impact on the cytokine 
level, such as intra-individual differences in 
physical activity and exercising. Chronic 
exercise training results in decreased levels of 
many circulating cytokines [41]. One of the 
donors was physically active, which explains 
the reduced cytokine level. The samples R1 and 
R2 were above the negative control owing to 
the IL-12p70 production. The IL-1 level was 
below the detection limit. The results indicate 
that Rad-PC-Rad liposomes hardly cause the 
production of pro-inflammatory cytokines in 
whole blood. Liposomes induce cytokine 
production as a result of the physicochemical 
parameters, i.e. size below 100 nm, surface 
charge (cationic lipids), and hydrophobicity 
[13]. We did not observe cytokine production 
upon the positive charge. Both positively 
charged Rad-PC-Rad liposomal formulations 
R1 and R3 showed unrelated variations of the 
elevated cytokine levels. The results show no 
indication that the liposomal size plays a role in 
cytokine production. The PEG-free samples R1 
and R3 with higher mean liposome diameters 
do not lead to elevated cytokines’ production. 
In all cases the response to the liposomes 
showed levels of pro-inflammatory cytokines 
comparable to the ones of saline or R5 medium 
(see Table S6). The main causes of increased 
cytokine production, however, are unknown, as 
immunotoxicity mechanisms relate to the 
composition of nanomaterials, the cell type and 
cycle, the animal model, and the disease status. 
The biological variability may have more 
impact on the immune reaction than expected. 
The possibility that certain results are 
attributable to endotoxin contamination [42] are 
valid, even though the samples were passed 
through a sterilized filter, and experiments were 
conducted under a sterilized hood. 
IL-8 is an essential chemokine involved in the 
recruitment of neutrophils to the site of 
inflammation. More than 50% of the tested 
nanomaterials, which induce the activation of 
pro-inflammatory cytokines, caused exclusive 
production of IL-8, without inducing TNF-α 
and IL-1. Besides, more than 50% of such 
inducers were liposomes and emulsions [15]. 
This phenomenon is not fully understood; 
however, a study suggests the involvement of 
oxidative stress [43]. 
Within the present study, the cytometric bead 
array test gave false positive results of IL-8. 
This means that the concentration of IL-8 in the 
negative and positive controls was above the 
standard concentration of the kit (see Table S6). 
Thus, we cannot conclude whether Rad-PC-
Rad liposomes induce the production of IL-8 or 
not. 
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Figure 7. The levels of SC5b-9 (A), C4d (B), Bb (C), C3a (D), and C5a (E) complement proteins. Human sera from five 
independent donors were incubated for a period of 40 minutes at a temperature of 37 °C with saline, nitroglycerin (NTG), 
Rad-PC-Rad liposomal suspensions of selected composition (R1, R2, R3, R4), Doxil® and AmBisome®. Saline solution was 
chosen as negative control. NTG was used as another negative control. Non-PEGylated liposomal formulations caused a 
higher level of C activation, mainly via the alternative pathway. The activation of the C cascade resulted in the increased 
production of C5a anaphylatoxin. The positive control zymosan caused substantially higher levels of complement activation. 
The data are represented as mean, including error bars derived from the standard deviation among the five donors. Each 
symbol and color represent data from a single donor. Significance of differences among the groups was determined by 
ordinary one-way ANOVA, followed by Dunnett's multiple comparisons test. P-values lower than 0.05 were considered as 
statistically significant.
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Limitations of the study 
Several studies on adverse reactions, which 
were very recently published, are based on six 
or less donors [17, 31, 44]. Thus, the choice of 
six donors in the present study seems to be 
reasonable. One out of the six donors showed a 
specific behavior, which is similar to reactions 
of some individuals to liposomal drugs. 
Therefore, a substantially higher number of 
donors should be incorporated into future 
studies and the presented results have a 
preliminary character. The present results, 
however, could support the selection of the 
number of donors. In literature, one usually 
finds numbers of ten and above [32, 34, 45]. 
We hypothesize that the false positive results, 
as observed in IL-8 production originate from 
the limitations of the multiplex array system, 
which necessitates the testing of the samples at 
multiple dilutions to detect lower and higher 
abundance cytokines. Another challenge in 
cytokine detection is their short half-live, such 
as six to seven minutes for TNF-α [46]. 
Furthermore, the prepared liposomes exhibited 
a wide variety of shapes and have to be 
regarded as a mixture of spherical and non-
spherical species. Additional efforts have to be 
invested to obtain a homogeneous and uniform 
size and shape distribution. 
 
Conclusions 
The extensive research interest of nanomedicines, whether biologically derived or synthetically created, 
draws attention to their immunotoxicity. Nanometer-sized species interact with the immune system 
according to their morphology and composition. C activation and cytokine response can induce 
immune-stimulation and potentially life-threatening conditions, including anaphylaxis and cytokine 
storm. Therefore, we have carefully studied the interactions of the artificially synthesized Rad-PC-Rad 
liposomes with cellular and humoral components of the innate immune system in human blood and 
obtained promising results. In summary, the experimental results indicate that Rad-PC-Rad liposomes 
are promising shear-responsive nano-containers and related in vivo experiments could be foreseen in 
near future. 
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46 2 Results
1. Materials used for the experiments 
The purchased chemical compounds were used without further purification. 
Table S1. List of materials used in the experiments.  
Name Company City, country 
DSPE-PEG2000 Lipoid AG Steinhausen, Switzerland 
Doxil® Janssen Cilag Ltd. Beerse, Belgium 
AmBisome® Gilead Sciences Ltd. Foster City, CA, USA 
Nitroglycerin Bioren 0.1% solution Sintetica SA Mendrisio, Switzerland 
0.9 % saline solution Bichsel AG Interlaken, Switzerland 
ELISA MicroVue kits  
(SC5b-9 Plus, C4d, Bb, C3a, C5a) Quidel Corp. San Diego, CA, USA 
FITC Annexin V Apoptosis Detection Kit BioLegend Ltd. Budapest, Hungary 
Cytometric Bead Array  
(Human inflammatory cytokine kit) BD Biosciences Budapest, Hungary 
Dulbecco’s phosphate buffered saline (DPBS) with and 
without CaCl2, MgCl2 
Sigma-Aldrich Co. Budapest, Hungary 
R5 cell medium consisting of Roswell Park Memorial 
Institute (RPMI) medium with Glutamine 
10 % Fetal Bovine Serum (FBS) 
0.1 mM non-essential amino acids (NEAAs) 
1 % penicillin-streptomycin solution 
50 µM β-mercaptoethanol 
1 mM pyruvate 
Ethylenediaminetetraacetic acid (EDTA) 
Zymosan 
Millex-GV 0.22 µm syringe filter Merck Millipore Ltd. Cork, Ireland 
Whatman Nuclepore Track-Etched Membranes Sigma-Aldrich Buchs, Switzerland 
PD-10 desalting columns GE Healthcare Bio-Sciences AB Uppsala, Sweden 
Hirudin-treated tubes Roche Kft. Budapest, Hungary 
50 mM 5(6)-carboxyfluorescein, powder 
Sigma-Aldrich Buchs, Switzerland 
10 mM HEPES buffer, powder 
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2. Calculation of NTG encapsulation efficiency  
Table S2. NTG encapsulation efficiency. 
Formula R3 R4 
Averaged [Mw] molecular weight (g/mol) 760.00 862.2748 
[C] measured conc. (g/L) 13.6 21.8 
[M] molarity (mol/L) = [C]/[Mw] 0.00132 0.00116 
Number of lipid molecules  
[No lipid mol] = [M] * Avogadro No  
7.92368´1020 6.98385´1020 
[D] liposome diameter (nm) 114.5 97 
[R1] liposome outer radius (nm) * 57.25 48.5 
Liposome outer area (nm2)  
[OA] = 4*3.14*R12 
41187.06438 29559.24477 
[R2] liposome inner radius (nm) ** 53.25 44.5 
Liposome inner area (nm2) 
[IA] = 4*3.14*R22 
35632.72867 24884.55498 
Total area per liposome (nm2) 
[TA] = [OA] + [IA] 
76819.79305 54443.79976 
[A] Area per lipid (nm2)*** 0.474 0.474 
Number of lipids per liposome  
[No lipids] = [TA]/[A] 
162067.074 114860.337 
Number of vesicles per 1L 
[N] = [No lipid mol] / [No lipids] 
4.88914´1015 6.0803´1015 
Volume of liposome (nm3)  
[V] = (4/3)*3.14*R23 
632480.9338 369120.8989 
Entrapped volume per 1L (nm3)  
[EV] = [N]*[V] 
3.09229´1021 2.24437´1021 
[EV] conversion nm3 into L per 1L;  
mL/mL 
0.003092287 0.002244365 
Area under curve [AUC] of NTG 100% signal in 1 mL 501428.6667 501428.6667 
Theoretical value of 100% signal in liposomes 
[EA]*[AUC] 1550.561388 1125.389191 
Measured value of % signal in liposomes 590.157 132.237 
Encapsulation efficiency of NTG (%) 
[EE] = [measured]/[theoretical]*100 
38.06 11.75 
* mean diameter from DLS measurement 
** R2 = R1 - 4 nm (thickness of bilayer) 
*** X-ray data, converted from Å2 to nm2 
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3. Differential scanning calorimetry (DSC) 
DSC were directly measured from the prepared Rad-PC-Rad and Rad-PC-Rad/DSPE-PEG vesicle suspensions. Liposomal 
suspensions were degassed for 30 minutes using a TA degassing station. The alternative heating-cooling scans were recorded on a 
TA Nano DSC (TA Instruments, USA) from 5 °C to 90 °C with a scanning speed of 0.5 K/min. The experiment was performed 
twice, starting with new suspensions, in order to ensure reproducibility. The scans of the second heating-cooling scans are reported 
in Figure S1. Raw data was baseline corrected and converted to molar heat capacity (MHC) using the NanoAnalyze software (TA 
Instruments, USA).  
 
 
Figure S1. DSC heating and cooling curves measured for Rad-PC-Rad and Rad-PC-Rad/DSPE-PEG vesicles. 
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4. Complement immunoassay 
The activation of the complement system is concentration- and time-dependent. Therefore, identification of the proper lipid 
concentration would help to avoid the appearance of unexpected side reactions. However, the applied concentration should be still 
therapeutically relevant. Therefore, before the conduction of the complement assay, we had to perform preliminary tests in order to 
find the appropriate lipid concentration for further studies. We tested two lipid formulations – R3 and R4. We started from the 
maximum concentration that we obtained after liposome preparation, which was 10 mg/mL. Those samples were diluted two, four 
and eight times. The observed results are presented in Figure S2. PEG-free sample R3 demonstrated an increase in complement 
activation, with increasing the lipid concentration. While PEG-containing sample R4 has shown slight decrease of SC5b-9 level 
with increasing the lipid concentration. Based on this preliminary result, we have decided to test Rad-PC-Rad liposomal 
formulations at two concentrations: 10 and 5 mg/mL. 
Figure S3 demonstrates the level of complement fragments, induced by incubation with Rad-PC-Rad liposomes at higher and lower 
concentrations (‘d’ indicates ‘diluted’ samples). As it was initially observed by a preliminary test, PEG-free liposomal formulations, 
R1 and R3, show a statistical significance in the complement activation between concentrated and diluted samples (Figure 3B, D); 
while PEG-containing formulations, R2 and R4, show no statistical difference. This phenomenon was partially true in case of C3a 
and C5a, because the observed differences were too small to be detected statistically. No differences were observed in the 
concentration of C4d fragment, as the lectin pathway is not involved in the activation of the complement system.  
 
Figure S2. The level of SC5b-9 protein complex after incubation of one human sera with R3 and R4 liposomal suspensions at four 
phospholipid concentrations: 1.25, 2.5, 5.0 and 10 µg/mL. Incubation was performed for a period of 40 min at 37 °C. 
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Figure S3. The level of SC5b-9 (A), C4d (B), Bb (C), C3a (D) and C5a (E) complement proteins after incubation of Rad-PC-Rad 
samples at two phospholipid concentrations: 10 µg/mL (R1, R2, R3, R4) and 5 µg/mL (R1d, R2d, R3d, R4d). Incubation was 
performed for a period of 40 min at 37 °C for all samples. Sera of donor #5 was excluded from the graph to better distinguish the 
contrast in complement activation between Rad-PC-Rad liposomal samples with and without DSPE-PEG. The data are represented 
as mean values with error bars derived from the standard deviation among six donors. The significance of differences among the 
corresponding groups was determined by paired T-test. P-values lower than 0.05 were considered as statistically significant. 
To further proceed with the analysis, we examined the level of complement activation over time. 
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Figure S4. The level of TCC at various time points. SC5b-9 concentration from six human sera incubated at 37 °C with the negative 
controls, Rad-PC-Rad liposomes at (A) higher lipid content (10 mg/mL) and at (B) lower lipid content (5 mg/mL), Doxil and 
AmBisome. The reaction was terminated after 5, 10, 20, and 40 minutes. The data are shown as the mean value among the five 
donors. The serum of donor #5 was omitted for clarity. 
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Table S3 provides the concentration values of complement proteins. Human sera from six independent donors were incubated for a 
period of 40 minutes at a temperature of 37 °C with saline, nitroglycerin (NTG), Rad-PC-Rad liposomal suspensions of selected 
composition (R1, R2, R3, R4), Doxil® and AmBisome®. 
Table S3. The concentration of SC5b-9, C4d, Bb, C3a and C5a complement proteins.  
Complement 
protein Donors 
Treatment samples 
Saline NTG R1 R2 R3 R4 Doxil® AmBisome® Zymosan 
SC5b-9 
(µg/mL) 
#1 3.81 4.69 14.16 6.53 39.48 7.11 7.52 17.30 199.52 
#2 3.33 3.74 10.19 6.22 16.04 7.98 6.27 22.02 198.94 
#3 2.50 2.96 25.30 8.06 58.67 22.68 4.86 36.95 177.28 
#4 3.35 3.67 15.94 6.74 32.43 7.17 4.73 45.19 182.59 
#5 5.99 7.66 169.08 158.85 166.79 150.99 8.30 47.91 171.66 
#6 5.40 5.92 23.39 13.12 49.23 17.97 8.36 51.90 252.54 
C4d 
(µg/mL) 
#1 1.49 2.01 1.83 1.49 1.93 1.61 1.55 1.35 1.78 
#2 1.64 1.75 2.44 2.16 2.33 1.85 2.52 2.42 3.00 
#3 1.42 1.72 2.06 1.88 1.65 1.42 1.33 2.16 2.25 
#4 2.15 3.39 2.63 2.12 2.25 1.92 2.26 3.19 3.42 
#5 5.42 6.63 1.58 2.59 3.18 4.28 4.57 5.96 7.04 
#6 6.80 6.52 5.77 5.73 5.03 5.49 2.50 2.27 3.88 
Bb 
(µg/mL) 
#1 7.02 7.89 13.39 7.07 16.50 10.27 13.08 19.20 40.39 
#2 6.00 7.04 15.48 7.77 12.87 10.15 10.39 24.58 44.80 
#3 5.03 5.00 16.50 8.56 17.67 15.00 8.77 24.44 29.00 
#4 5.92 6.83 10.63 9.03 14.31 9.91 17.93 27.53 33.76 
#5 7.69 9.91 59.83 30.94 41.79 33.71 10.15 30.56 36.87 
#6 7.82 9.35 16.59 10.25 16.23 15.67 13.39 34.53 51.03 
C3a 
(ng/mL) 
#1 4.43 4.66 11.01 4.37 10.46 6.42 6.01 12.08 18.51 
#2 2.48 3.12 10.23 4.25 7.49 6.16 7.39 15.63 18.80 
#3 5.12 5.38 18.98 9.58 17.62 18.69 11.28 26.09 21.27 
#4 4.62 7.23 9.72 8.97 12.87 8.48 8.89 25.46 20.98 
#5 7.74 12.81 24.20 5.39 15.51 14.74 11.86 25.98 14.60 
#6 5.55 8.14 14.84 7.88 9.38 11.09 10.76 6.53 20.61 
C5a 
(ng/mL) 
#1 70.36 82.12 110.56 70.54 218.23 66.71 48.75 152.44 1471.22 
#2 56.86 50.12 88.96 66.26 115.40 92.51 69.72 171.31 1488.54 
#3 26.96 20.22 111.75 52.49 183.86 108.38 30.61 141.23 748.25 
#4 29.61 29.06 64.52 47.75 141.65 42.46 33.43 192.78 759.19 
#5 32.51 42.00 587.64 677.53 561.06 561.41 45.10 204.00 791.10 
#6 38.27 35.08 113.02 72.45 128.16 110.84 59.05 231.35 1344.49 
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5. Qualitative and quantitative analysis of WBCs 
  
 
Figure S5. Gating strategy (upper panels) to identify the absolute cell concentration of samples’ cells by flow cytometry. Scatter 
plot (lower panel, SSC/SSC) of gated cells is presented by the same color. 
The cell content of samples was analyzed by flow cytometry using a FACScan instrument (BD Biosciences, USA). Before the actual 
tests, 50 µl of the cells were stained by antibody mixture containing fluorescein isothiocyanate (FITC) labeled anti-CD14, 
phycoerythrin (PE) labeled anti-CD11b and PerCP-Cy5.5 labeled anti-CD45 in TRUCount tubes (BD, cat.: 340334) for 15 min in 
the dark. Thereafter, WBC were resuspended in 450 µL of lysing solution (BD, cat.: 349202) for 15 min. As the employed 
TRUCount tubes contained a known number (48 100) of beads (gating name: TRU) measured together with cells, the exact cell 
concentrations of the original samples could be identified, since no centrifuge step was applied during the sample staining process.  
After gating, which strategy is summarized in Figure S5, the concentration and total cell number of monocytes (Mo), neutrophil 
granulocytes (Ne) and lymphocytes (Ly) was quantitatively determined as it is presented in Table S4. The number of WBCs was 
determined prior to the incubation with tested material. In case of buffy coat samples, the number of cells was determined twice: 
before (original) and after isolation of leukocytes. Cells were stained according to the procedure described above.  
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Table S4. Concentration of WBCs in the buffy coat (BC), before and after leukocytes isolation, and in whole blood (WB) samples. 
 Cell concentration (cell/mL) 
 Monocytes Neutrophils Lymphocytes Total cells 
BC1 original 2'364'360 17'869'287 15'101'890 35'335'536 
BC1 isolated cells 4'059'419 15'811'548 16'888'079 36'759'046 
BC2 original 1'915'442 12'791'686 11'303'143 26'010'271 
BC2 isolated cells 19'003'419 100'469'999 67'771'808 187'245'226 
BC3 original 2'105'082 18'639'499 11'822'281 32'566'862 
BC3 isolated cells 25'539'472 171'957'831 67'099'037 264'596'339 
WB1  310'963 2'223'685 2'014'609 4'549'258 
WB2  372'776 2'214'462 2'596'503 5'183'741 
 
The viability of the cells after activation with test material and control agents was quantified by FITC labeled AnnexinV (Table S5) 
among (PerCP-Cy5.5 labeled) CD45 positive leukocytes. The percentage of dead cells were less than 3% after each treatment with 
the exception of zymosan, confirming that the observed phenomena in cytokine productions are not a consequence of different cell 
mortality after treatments. 
Table S5. Cell viability assay of isolated leukocytes and whole blood after activation with liposomal formulations and corresponding 
control agents. 
 Viable cells (%) 
Sample PBS MR5 R1 R2 R3 R4 Zymosan 
BC2 98.4 98.18 98.06 98.12 98.34 98.37 64.32 
WB2 97.57 98.43 97.49 97.75 97.53 97.95 60.52 
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6. Concentration of inflammatory cytokines 
Table S6 provides the concentration values of inflammatory cytokines. WB and BC samples were incubated with R5 medium, PBS, 
Rad-PC-Rad liposomal suspension of selected composition (R1, R2, R3, R4) and zymozan at a temperature of 37 °C.  
Table S6. The concentration of IL-6, IL-12p70, TNF-α, IL-1b, IL-8 and IL-10 inflammatory cytokines. 
Cytokines Donors 
Samples 
MR5 PBS R1 R2 R3 R4 Zymosan 
IL-6 
(pg/mL) 
WB1 1086.69 1950.84 15.83 1848.47 36.11 144.90 >5000.00 
WB2 98.70 86.46 0.98 81.19 14.65 86.46 >5000.00 
BC1 9.24 1.15 9.75 5.19 6.21 9.58 na 
BC2 1.32 nd 11.44 nd nd nd >5000.00 
BC3 nd nd nd nd nd nd >5000.00 
IL-12p70 
(pg/mL) 
WB1 1.80 2.00 3.40 1.20 1.20 2.00 20.51 
WB2 0.00 0.60 1.00 42.28 1.20 1.40 2.20 
BC1 1.20 0.80 1.00 1.20 1.00 1.40 na 
BC2 0.80 0.80 0.60 1.20 0.40 1.00 8.03 
BC3 1.00 0.80 1.00 1.40 0.80 0.60 4.20 
TNF-α 
(pg/mL) 
WB1 230.91 596.55 18.63 536.73 11.41 52.42 >5000.00 
WB2 10.83 11.80 0.50 12.19 5.57 12.97 >5000.00 
BC1 nd nd nd nd nd nd na 
BC2 nd nd nd 12.00 nd nd 4519.33 
BC3 nd nd nd nd nd nd 1656.93 
IL-1b 
(pg/mL) 
WB1 212.39 319.06 10.44 279.20 6.53 22.32 >5000.00 
WB2 7.24 3.33 2.14 4.16 2.14 5.93 >5000.00 
BC1 28.62 19.59 9.02 8.19 9.61 13.89 na 
BC2 7.24 7.12 11.04 8.66 16.62 7.60 >5000.00 
BC3 9.37 7.60 9.02 7.83 16.62 9.61 >5000.00 
IL-8 
(pg/mL) 
WB1 >5000.00 >5000.00 4033.03 >5000.00 4747.50 >5000.00 >5000.00 
WB2 >5000.00 >5000.00 1497.28 >5000.00 2835.68 4565.74 >5000.00 
BC1 >5000.00 >5000.00 >5000.00 >5000.00 >5000.00 >5000.00 na 
BC2 >5000.00 >5000.00 >5000.00 >5000.00 >5000.00 >5000.00 >5000.00 
BC3 >5000.00 >5000.00 >5000.00 >5000.00 >5000.00 >5000.00 >5000.00 
IL-10 
(pg/mL) 
WB1 nd nd nd 0.69 nd nd 151.91 
WB2 nd nd nd nd nd nd 148.40 
BC1 nd nd nd nd nd nd na 
BC2 nd nd nd nd nd nd 314.32 
BC3 nd nd nd nd nd nd 196.37 
Cytokines detection limit (pg/mL): IL-6 – 2.5, IL-12p70 – 1.9, TNF-α – 3.7, IL-1b – 7.2, IL-8 – 3.6, IL-10 – 3.3. nd – not detected, 
na – not available. 
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2.3 Small-angle neutron scattering study of
temperature-induced structural changes in liposomes
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Small-Angle Neutron Scattering Study of Temperature-Induced
Structural Changes in Liposomes
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and Bert Müller*,†
†Biomaterials Science Center, Department of Biomedical Engineering, University of Basel, Allschwil 4123, Switzerland
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ABSTRACT: Liposomes of speciﬁc artiﬁcial phospholipids, such as
Pad-PC-Pad and Rad-PC-Rad, are mechanically responsive. They can
release encapsulated therapeutics via physical stimuli, as naturally present
in blood ﬂow of constricted vessel segments. The question is how these
synthetic liposomes change their structure in the medically relevant
temperature range from 22 to 42 °C. In the present study, small-angle
neutron scattering (SANS) was employed to evaluate the temperature-
induced structural changes of selected artiﬁcial liposomes. For Rad-PC-
Rad, Pad-Pad-PC, Sur-PC-Sur, and Sad-PC-Sad liposomes, the SANS
data have remained constant because the phase transition temperatures
are above 42 °C. For Pad-PC-Pad and Pes-PC-Pes liposomes, whose
phase transitions are below 42 °C, the q-plots have revealed temperature-dependent structural changes. The average diameter of
Pad-PC-Pad liposomes remained almost constant, whereas the eccentricity decreased by an order of magnitude. Related
measurements using transmission electron microscopy at cryogenic temperatures, as well as dynamic light scattering before and
after the heating cycles, underpin the fact that the non-spherical liposomes ﬂatten out. The SANS data further indicated that, as
a consequence of the thermal loop, the mean bilayer thickness increased by 20%, associated with the loss of lipid membrane
interdigitation. Therefore, Pad-PC-Pad liposomes are unsuitable for local drug delivery in the atherosclerotic human blood
vessel system. In contrast, Rad-PC-Rad liposomes are thermally stable for applications within the human body.
■ INTRODUCTION
Liposomes are composed of lipid bilayers and usually have a
spherical shape.1 Using artiﬁcial phospholipids with a
dedicated backbone chemistry and tail length that form
interdigitated bilayers, facetted liposomes have been discov-
ered.2 These liposomes are beneﬁcial in medical therapies
because they possess distinctive characteristics. As conven-
tional liposomes, they can encapsulate therapeutic molecules
and transport them to the desired location, preventing direct
contact between drug and blood. Upon mechanical stimuli,
however, these liposomes can undergo structural changes to
release the cargo.3 In this manner, the totally administered
dose and the related objectionable side eﬀects along the
patient’s 60 000-miles-long blood vessel system being currently
ﬂooded with the drug can be kept extremely low, whereas the
purely physical trigger renders possible an unrivaled local dose
to pathological constrictions.
The thermal stability of these facetted liposomes within the
physiologically relevant temperature range, however, has hardly
been studied yet. It is well known that the body temperature is
generally close to 37 °C. On grounds of ill health, the body
temperatures can raise to above 40 °C, but at a temperature of
42 °C the circulation fails. Hypothermia, as, for example,
intentionally induced during heart surgery, gives rise to body
temperatures close to 20 °C.4 Therefore, the present study
covers the temperature range between 22 and 42 °C.
The size and shape of liposomes including their distributions
can be assessed by employing dynamic light scattering (DLS)
and cryogenic transmission electron microscopy (cryo-TEM).
For the structural characterization of the lipid bilayer thickness,
however, a technique with better resolving power is needed.
Therefore, we applied small-angle neutron scattering (SANS)
as a tool to obtain quantitative information about the structural
parameters of liposomes as the function of temperature. SANS
allows for the investigation of fully hydrated systems, oﬀering
the additional feature of contrast variation via solvent
exchange. More importantly, our setup was equipped with a
heating stage to conveniently control the temperature of the
liposomal suspensions within the medically relevant range.
Liposomes from DPPC exhibit a spherical shape. Non-
spherical shapes can be obtained replacing the 1,2- by the 1,3-
arrangement of the fatty acyl chains in the backbone as found
in Pad-PC-Pad, Rad-PC-Rad, Pes-PC-Pes, Sur-PC-Sur, and
Sad-PC-Sad, see Figures 1 and 2 below. This arrangement
increases the spacing between the chains and leads to
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58 2 Results
interdigitated lipids in the membrane. Longer carbon chains
improve the thermal stability by increasing the hydrophobic
forces between the chains, revealed by an increase in the
transition temperature. Because this class of liposomes has
substantially stiﬀer lipid bilayers than the established natural
membranes, facetted liposomes with speciﬁc defects and
related mechanical features can be tailored. Pad-PC-Pad and
Rad-PC-Rad as well as the less reported Pes-PC-Pes, Pad-Pad-
PC, Sur-PC-Sur, and Sad-PC-Sad lipids belong to a family that
forms metastable non-spherical liposomes. Their interdigitated
lipid bilayers are thinner and more rigid than the conventional
ones such as the well-established DPPC liposomes. They
exhibit a distinct curvature in only one direction associated
with defect lines. Therefore, these non-spherical liposomes
represent a metastable state, and the application of mechanical
or thermal energy can result in structural changes. The
mechanical stimulation was already studied in some detail,5
whereas the thermal characterization was mainly restricted to
the measurement of the main membrane phase transition
temperature from a gel to the liquid crystalline phase.3,6
In this study, we detect temperature-dependent changes in
the size, shape, and bilayer properties of liposomal
formulations, composed of the family of selected artiﬁcial
phospholipids, and, in this regard, the structural changes at
medically relevant body temperatures are of particular interest.
■ MATERIALS AND METHODS
Liposome Preparation. The lipids were synthesized as
reported.3,6−9 The liposomes were formulated following the standard
extrusion protocol.10 Brieﬂy, 10 mg of lipids were dissolved in
CH2Cl2. After evaporating the organic solvent, the thin ﬁlm was dried
further under vacuum conditions with a pressure of 40 mbar
overnight. The ﬁlm was hydrated with D2O for a period of 30 min.
Five freeze−thaw cycles from liquid nitrogen temperature to 65 °C
were carried out and followed by eleven extrusion cycles, using a Mini
Extruder (Avanti Polar Lipids, USA) and track-edged ﬁlters with
Figure 1. SANS data and related cryo-TEM images of liposomal suspensions reveal temperature-induced structural changes close to their transition
temperatures Tm. The structural representations of the phospholipids show color-coded chemical motives. The inset diagrams display the scattering
signal for higher q-values, before (black circles) and after (blue circles) heating and the related ﬁts using the generalized Guinier law. The scale bars
of the TEM micrographs correspond to 100 nm, where black and blue indicate imaging was recorded before and after the heating cycle,
respectively. Diagram (D) provides the reader an idea how far the liposomes can be approximated by spheres, ellipsoids, or discs. The goodness of
ﬁt, described by reduced chi-square, is for the spheres 91.2, 30.1, 51.0, for the ellipsoids 21.7, 178.7, 17.6, and for the discs 65.4, 18.3, 237.0 at the
temperatures 32, 35 and 39 °C, respectively. To suitably visualize the diﬀerences, the values for 35 and 39 °C were shifted with respect to those for
32 °C along the ordinate by a factor of three and 10, respectively.
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100 nm pore size (Whatman, USA). The obtained liposomal
formulations exhibited a lipid concentration of about 10 mg/mL.
Dynamic Light Scattering. The DLS traces were measured using
the DelsaMax PRO apparatus (Beckman Coulter, USA). Here, the
photodiode is positioned at 168° backscatter angle and detector
position at 163.5° associated with scattering angles ranging from 4 to
15°. The measurements were carried out at room temperature and at
a lipid concentration of 0.3 mg/mL in D2O. The data were averaged
among ﬁve independent measurements before heating cycles and
three measurements eight months after applying the heating cycles.
The data were treated with the cumulant analysis method.
cryo-Transmission Electron Microscopy. The liposomal
suspensions were diluted at a ratio of 1:2 with D2O and thus to a
concentration of 5 mg/mL. Next, 4 μL aliquots of each suspension
were adsorbed onto a holey carbon-coated grid (Lacey, Ted Pella,
USA), blotted with Whatman 1 ﬁlter paper and vitriﬁed into liquid
ethane at a temperature of −178 °C, using a Leica GP plunger (Leica,
Austria). Frozen grids were transferred onto a Talos electron
microscope (Thermo Fisher, USA), using a Gatan 626 cryo-holder.
Electron micrographs were recorded at an accelerating voltage of
200 kV and a nominal magniﬁcation of 45 000×, using a low-dose
system (0.20 e−/nm2) and keeping the sample at liquid nitrogen
temperature. Micrographs were recorded on the CETA camera. Pixel
size at the sample level was (0.326 nm)2. Because some of the cryo-
TEM micrographs exhibited slowly varying brightness variations, we
compensated for such artefacts using a modiﬁed fuzzy C-means
algorithm.11,12
Small-Angle Neutron Scattering. The SANS measurements
were performed at the SANS-I facility, Swiss Spallation Neutron
Source SINQ, Paul Scherrer Institute, Switzerland. Neutrons with an
energy of 400 meV, which corresponds to a wavelength λ of 0.045 nm,
were used at sample-to-detector distances of 1.6, 6.0, and 18.0 m and
exposure times of 190 and 564 s. In addition, neutrons with an energy
of 60 meV (λ = 0.12 nm) at a sample-to-detector distance of 18.0 m
and an exposure time of 950 s were employed. The wavelength’s
spread was about 10%. This choice of parameters allowed for the data
collection over the range of scattering vectors q between 0.01 and
10 nm−1, required to observe both the global size and shape of
liposomes as well as their membrane thickness. The samples were
loaded into 2 mm-path length boron-free quartz glass cells and
mounted in the temperature-controlled holder. This system allows for
controlling the temperature of the specimen with an accuracy better
than 1 K. The liposomal suspensions were measured between 22 and
42 °C in 3−4 K steps. Subsequently, the suspensions were cooled
down to 22 °C (room temperature) and measured again. The
scattering data were collected with a two-dimensional 3He-detector
using an array of 128 × 128 pixels. They were radially averaged to
obtain the one-dimensional I(q) signals using the scattering angle θ
Figure 2. SANS data and cryo-TEM images of Rad-PC-Rad, Pad-Pad-PC, Sur-PC-Sur, and Sad-PC-Sad liposomes hardly show any thermal eﬀect,
because the transition temperatures Tm are above the medically relevant range. The structural representations of the phospholipids show color-
coded chemical motives, i.e. the C16 chaindark blue, the C17 chainlight blue, and the C18 chainpurple. The inset diagrams display the
scattering signal for higher q-values, before (black circles) and after (blue circles) heating and the related ﬁts using the generalized Guinier law. The
scale bars of the micrographs correspond to 100 nm.
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The data were corrected for transmission, background scattering,
and detector eﬃciency according to a standard procedure using the
BerSANS software package.13,14
Models Used for SANS Data Analysis. The SANS data were
analyzed using the SASﬁt software15 and the implemented models.
The datasets of Pad-PC-Pad and Rad-PC-Rad liposome suspensions
were ﬁtted over the entire q-range measured. Here, we used the
spherical, ellipsoidal shell and discs models with a homogeneous
cross-section16 and size distributions in terms of both thickness and
radius. The elliptical shell model is deﬁned by three orthogonal axes
with lengths a = b = R and c = εR, along with eccentricity ε > 0, (ε <
1: oblate, ε = 1: spherical, and ε > 1: prolate). For Pad-PC-Pad, we
also included the sticky hard sphere model17,18 to account for inter-
particle interactions, as it deﬁnes the stickiness parameter, which
characterizes the adhesive strength and helps to describe liposome
aggregation. The ﬁts of the other liposomal suspensions were
restricted to the q-range related to the lipid bilayer thickness. Here,
we used a generalized Guinier approximation19,20 to extract the
bilayer thickness. This approximation is extended to planar objects
and based on local planes with a homogeneous cross section. It does
not include any assumption of the overall shape of the liposomes and
is given by
π= − αI q q A R q( )
2
exp( )2
2 2
(2)
where A is the constant pre-factor, see for example ref 20.
The bilayer thickness t was calculated according to
= αt R12 (3)
The bilayer thickness is orders of magnitude smaller than the
diameter of the liposomes. In such case, the form factor can be
factorized.21 Therefore, the extraction of the bilayer thickness is
allowed without loss of quality.
Multi-lamellar contributions for DPPC, Pad-Pad-PC, Pes-PC-Pes,
and Sur-PC-Sur were integrated using the para-crystalline theory.22,23
■ RESULTS
Liposome Characterization by Dynamic Light Scat-
tering. Table 1 lists the hydrodynamic diameter and
polydispersity of the liposomes before (n = 5) and after (n =
3) the thermal cycles performed for the temperature-
dependent SANS measurements. The main phase transition
temperatures Tm are known.
3,6,8,9,24 In the course of the SANS
experiments, the liposomes underwent heating to 42 °C and
back to room temperature, which resulted in substantial
changes of hydrodynamic sizes and the polydispersity indices.
In general, the liposomes showed an increase in size, which
could be understood by aggregation owing to the low repulsive
forces between the basically neutral liposomes. The exception
was found for Pad-PC-Pad liposomes, which exhibited a
decrease by a factor of two. This result for the DLS
measurements was conﬁrmed using cryo-TEM.
Small-Angle Neutron Scattering Measurements.
Figures 1 and 2 summarize the temperature-dependent
neutron scattering experiments for the liposomes with Tm
below and above 42 °C, respectively. The SANS experiment
almost covers the entire nanometer range because the q-range
from 0.01 to 3 nm−1 corresponds to real-space periodicities
between 2 and 600 nm. Liposomes, however, have aperiodic
spacing and, thus, the maximum liposome diameter, that can
be determined, is given by π/qmin ≈ 300 nm. Therefore, only
some of the liposomal suspensions can be characterized with
respect to the liposome size, but the SANS data allow
measuring the lipid bilayer thickness for all of them.
The bilayer thickness of the selected liposomes for the
medically relevant temperature range is compiled in Tables 2
and 3. As expected, the liposomes with a transition
temperature above 42 °C do not exhibit any change in bilayer
thickness. Pes-PC-Pes and Pad-PC-Pad liposomes, however,
show the tendency for losing interdigitation of the lipid
bilayers already well below Tm.
The well-established DPPC liposomes were incorporated
into the study for comparison. The decrease of forward
scattered intensity for DPPC with increasing temperature is
likely caused by increasing repulsive interactions associated
with the pre-transition temperature of DPPC, which varies
between 33.5 and 35.8 °C, and is even 37.4 °C in case of the
use of D2O.
25 This hypothesis has to be veriﬁed by a future
study. The mean size of the DPPC liposomes, as derived from
cryo-TEM images and represented exemplarily in Figure 1A,
was (87 ± 20) nm, and about 16% of them were multi-
lamellar. The SANS data of Pes-PC-Pes liposomes, see Figure
Table 1. Results of the Dynamic Light Scattering from the Liposomes Useda
before heating after heating
lipid Tm, °C size, nm PDI size, nm PDI
DPPC 41 120 ± 2 0.01 ± 0.01 600 ± 40 0.33 ± 0.02
Pad-PC-Pad 37 126 ± 4 0.19 ± 0.04 53 ± 4 0.33 ± 0.04
Rad-PC-Rad 45 150 ± 3 0.57 ± 0.01 700 ± 100 0.32 ± 0.03
Pes-PC-Pes 39 170 ± 20 0.57 ± 0.01 3100 ± 200 0.92 ± 0.08
Pad-Pad-PC 40−47 1500 ± 30 0.57 ± 0.01 n.a.b n.a.
Sur-PC-Sur 47 400 ± 100 0.57 ± 0.01 n.a. n.a.
Sad-PC-Sad 52 160 ± 3 0.23 ± 0.01 220 ± 10 0.20 ± 0.02
aThe errors originate from the standard deviations of independent measurements. bHere, n.a. means the data could not be extracted because of
aggregate size.
Table 2. Most Probable15 Bilayer Thickness (nm) of the
Selected Liposomes as a Function of Temperaturea
temperature, °C
phospholipid 22 25 28 32 35 39 42 22
DPPC 4.6 4.6 4.6 4.6 4.6 4.7 4.7 4.7
Rad-PC-Rad 4.6 4.6 4.6 4.5 4.5 4.4 4.4 4.5
Pad-Pad-PC 5.6 5.6 5.6 5.5 5.5 5.6 5.6 5.7
Pes-PC-Pes 3.9 4.2 4.5 4.4 4.6 4.7 4.6 4.8
Sur-PC-Sur 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1
Sad-PC-Sad 3.2 3.5 3.5 3.5 3.5 3.4 3.3 3.0
aThe goodness of the ﬁt, described by reduced chi-square, varies
between 3 and 15.
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1B, indicate the presence of two liposome populations with
sizes of about 100 and 1000 nmno plateau at low q-values
and of stacked lipid bilayersprominent BRAGG peak at
q = 0.83 nm−1. Increasing the temperature, the peak gradually
diminishes associated with the disintegration of the stacked
lipid bilayers.
The ﬁtting of the SANS data for Pad-PC-Pad liposomes was
especially challenging. Therefore, not only the bilayer thickness
was determined but also their radius and eccentricity. The
radius was not aﬀected by the temperature cycle, whereas the
eccentricity abruptly changed already well below the transition
temperature, i.e. between 32 and 35 °C. This change in shape,
however, is not linked with the increase of the bilayer
thickness, which has been observed after cooling-down to
room temperature. The shape change of Pad-PC-Pad lip-
osomes from ellipsoidal or better facetted entities to discs as
the result of the heating was validated by the cryo-TEM
images, exemplarily displayed in Figure 1C.
For Rad-PC-Rad, Pad-Pad-PC, Sur-PC-Sur, and Sad-PC-Sad
liposomes, the q-plots derived coincide, which proves their
thermal stability within the medically relevant temperature
range. The ﬁtting of SANS data for Rad-PC-Rad liposomal
suspensions was challenging, easily explained by the presence
of their size and shape distributions indicated in the
micrographs of Figure 3A. Figure 3B exemplarily summarizes
the ﬁtting of the data obtained at a temperature of 42 °C.
Ignoring the inter-particle interactions and considering
ellipsoid shape, one can ﬁnd a better approximation than for
the discoid model. The goodness of ﬁt, described by reduced
chi-square, is for spheres 11.4, for ellipsoids 30.3, and for discs
47.8. The thermal stability of the Rad-PC-Rad liposomes with
their wide-spread size and shape distribution within the
medically relevant temperature range, however, is the key
observation and more essential than the selection of the most
appropriate model.
■ DISCUSSION AND CONCLUSIONS
The bilayer thickness of the DPPC liposomes derived in this
study perfectly agrees with the values reported,26,27 which
indicates an appropriate ﬁtting procedure. The liposomes of
Pes-PC-Pes, also known as β-DPPC, exhibit interdigitated lipid
bilayer in the gel phase but not in the liquid crystalline phase.28
Therefore, the phase transition results in a bilayer thickness
increase by 20%28a value consistent with the present study.
The study also shows that the changes in the tail-to-tail Van der
Waals forces and inter-head-group hydrogen bonding in the
series from Pad-Pad-PC via Sur-PC-Sur to Sad-PC-Sad do
hardly aﬀect the overall properties of the liposomes. Likewise,
Pad-PC-Pad lipids are interdigitated below Tm and lose this
structural property at higher temperatures.3,8 In agreement
with the present study, recent SAXS data have indicated that
the head-to-head distance of Pad-PC-Pad bilayer increases as
the result of mechanical stimuli.5 The observed 20% increase in
bilayer thickness after heating above Tm denotes thermally
induced structural changes. These structural changes of Pad-
PC-Pad liposomes within the physiologically relevant temper-
ature range is counter-indicative of its use as a carrier for
targeted drug delivery in humans.
The C17 homologue of Pad-PC-Pad, that is, Rad-PC-Rad,
which features a higher transition temperature,6 should allow
for mechanically responsive drug delivery within the human
body. Although the used Rad-PC-Rad liposomes possess a
wide variety of sizes and shapes, they show the structural
stability at the level of the bilayer membrane in the
Table 3. Structural Data Derived from SANS Demonstrate the Pad-PC-Pad Liposome Shape Changes Close to Tm
a
temperature, °C radius, nm eccentricity bilayer thickness, nm reduced chi-square
22 70 ± 19 0.35 3.5 ± 1.1 18.9
25 66 ± 21 0.35 3.4 ± 0.9 18.1
28 70 ± 16 0.32 3.3 ± 0.9 22.4
32 70 ± 16 0.31 3.4 ± 0.9 21.7
35 70 ± 7 (65) 0.1 (0.88) 3.3 ± 0.7 (3.4 ± 0.9) 178.7 (19.2)
39 72 ± 5 0.04 3.4 ± 0.8 17.5
42 71 ± 5 0.05 3.6 ± 0.7 107.1
22 70 ± 32 0.04 4.2 ± 0.7 9.4
aAt a temperature of 35 °C, the contribution for discs with homogeneous cross-section was accounted forvalues in brackets.
Figure 3. (A) Exempliﬁed cryo-TEM images verify the manifold shapes and sizes of the Rad-PC-Rad liposomes used. The scale bars correspond to
a length of 500 nm. (B) Discs less suitably describe the SANS data of Rad-PC-Rad liposomes than the ellipsoidal and spherical models.
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physiologically relevant temperature range between 22 and
42 °C.
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3 Conclusions and Outlook
In the framework of the current thesis project, mechano-responsive liposomes of
nanometer size, designed for physically-triggered drug delivery within the diseased
human blood vessel system, were carefully prepared and in-depth characterized. The
structural characterization of the Pad-PC-Pad liposomes as a function of the physio-
logically relevant temperatures by means of SANS has revealed that these liposomes
are thermally not stable enough for the application beyond mucosa. Rad-PC-Rad
liposomes with diameters of around 100 nm — even with a wide variety of shape
— however, they exhibit the necessary thermal stability to be used for the dilation
of atherosclerotic human arteries. In order to obtain homogeneous liposomal sus-
pensions, future work should focus on the improvement of the preparation protocol.
The clustering of the liposomes, as the consequence of the low zeta potential, can
be prevented by PEGylation, so that these liposomes are promising nanocontainers
for the envisioned targeted treatment of atherosclerosis.
The nitroglycerin-loaded Rad-PC-Rad liposomes, formulated from artificial phos-
pholipids, should be parenterally administered. The related safety concerns can be,
inter alia, addressed detecting the complement activation to quantify the immune-
mediated adverse effects. Herein, the ELISA assay has been performed to determine
the level of complement proteins activated in serum upon incubation with liposomes.
The experiments with Rad-PC-Rad liposomes have verified a level of complement
proteins low-to-moderate relative to the currently available FDA-approved liposomal
drugs. The activation of the complement cascade was initiated via the alternative
pathway, as found for both Pad-PC-Pad and Rad-PC-Rad liposomes. The results
are, however, preliminary, since the number of donors for complement activation has
to be increased to the order of one hundred. Future studies should not only focus
on complement activation, but include preclinical evaluations, comprising the detec-
tion of hemolysis, platelet aggregation, oxidative stress, cell viability, phagocytosis,
contamination, etc.
Additional investigations must be conducted before human trials can start. The
structural changes of the nanometer-size, nitroglycerin-loaded Rad-PC-Rad lipo-
somes under physiological flow conditions, mimicking the shear stress of constricted
arteries, at temperatures up to 42 °C have to be identified. Future studies should
include the pharmacokinetic and pharmacodynamic efficacy of nitroglycerin-loaded
liposomes in comparison to the current systemic use of nitroglycerin. Finally, in
vivo studies should yield the desired dosage in a patient-specific manner.
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